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Introduction
A main goal of anesthesiologists is to protect their patients from risks associated
with surgery. The stress response to tissue injury is a natural response which
generally restores tissue homeostasis. However, the physiological effects associ-
ated with a large stress response or a defective stress response may be a major risk
for patients having surgery. Therefore, anesthesiologists should further refine
their strategies to control the surgical stress response.However, this is not an easy
task.
Surgical procedures such as reposition of fractured bones and trepanation of
the skull have been performed since prehistoric times1. However, it is only for
about one century that the systemic adaptive response associated with these
procedures has attracted the interest of scientists. First, physiologists introduced
terms related to adaptive systems in general such as: “milieu interieur” (Claude
Bernard, 1898) “homeostasis” and “fight or flight” (Walter Cannon, 1929).
Later, terms in relation to the stress of tissue injury were introduced like “meta-
bolic stress response”(D. Cuthbertson, 1932), “general adaptation syndrome”
(Hans Selye, 1936) and “wound hormones”(Egdahl, 1959). Since then a
growing number of studies continue to reveal the enormous complexity of the
stress response to tissue injury. This complexity is not surprising because there
are data indicating that this response is also present in fish and therefore has
evolved over more than 400 million years2. Our current understanding of this
response may be summarized as follows (fig. 1). Tissue trauma initiates a local
inflammatory response that, through blood-borne and neuro-sensory signals,
initiates a systemic stress response with the ultimate goal to restore homeostasis.
In general, the stress response to tissue trauma may be divided into an immuno-
logical component and a neuro-endocrine component3. The immunological
component,which includes activation of the inflammatory response and ampli-
fication of the innate (natural) immune system, is important for tissue healing
and prevention of infections. The neuro-endocrine component, which consists
of activation of the autonomic nervous system and of the hypothalamic-pitu-
itary-adrenal (HPA) axis, has an important role in providing energy sources for
the injured tissue.Additionally it helps to prevent an overreaction of the inflam-
matory-immunological response. It is important to realise that these two
components of the systemic stress response are tightly interconnected3-5. For
example, cytokines, important mediators of the inflammatory-immune
response, are known to stimulate the HPA axis. Conversely, immune cells
contain receptors for hormones and transmitters of the HPA axis. In addition to
this hormonal interaction between both systems there is exciting evidence that
the nervous system may directly control the immune system5.
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Homeostasis may not be restored if the stress response is too weak or too
strong in relation to the stressor or in relation to the patient. If the stress response
is too weak the patient suffers from infections and impaired tissue healing. In
contrast, excessive inflammatory or neuro-endocrine responses may result in the
systemic inflammatory response syndrome or excessive cardiovascular activation
respectively. Especially in patients at the extremes of ages and in patients having
co-morbidity this may cause significant morbidity.
The introduction of anesthetic techniques in the 19th century was a key
event in surgical practice because the associated sedation and tissue relaxation
allowed for increasingly invasive surgical procedures. However, patients
frequently died after major surgical procedures. Later, a study in neonates
showed the importance of attenuation of the neuro-endocrine stress response in
reducing postoperative morbidity and mortality6. Also, various studies in adults
suggested an important relation between the neuro-endocrine stress response
and adverse cardiac outcome after surgery. So, diminishing the neuro-endocrine
stress response to surgery became a major goal for anesthesiologists.
INTRODUCTION
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Figure 1 Schematic representation of the stress response to tissue injury.
Symp NS: sympathetic nervous system; Parasym NS: parasympathetic nervous system.
Recently, evidence has emerged that inflammatory immunological
phenomena underlie postoperative complications such as the systemic inflam-
matory response syndrome, postoperative infections, and coronary thrombotic
events7,8. Additionally, there is evidence that anesthesiological techniques can
affect these immunological phenomena9. So, anesthesiological techniques may
improve outcome from their effect on both the neuro-endocrine and the
immunological component of the stress response.
Various recent developments in health care have created a renewed interest in
strategies to modulate the surgical stress response. Also, the research questions in
this thesis may be seen as part of this renewed interest. The main focus of these
questions is on modulation of the stress response in relation to the cardiovascular
system.This is because cardiovascular complications have an important effect on
postoperative outcome.
A first development in health care is that economic forces have resulted in
surgical programs aiming at a faster recovery from anesthesia and surgery.
However, these fast track surgical programs incorporate the use of short-acting
anesthetic drugs, and thus may leave the patient relatively unprotected from
potential harmful stress responses during the early period after major surgery10.
One fast track anesthetic strategy for cardiac surgery is a technique based on the
short-acting opioid remifentanil, which allows for the intra-operative use of
high dose opioids without delaying extubation11 . Alternatively, an anesthetic
technique based on thoracic epidural analgesia can be used. This is because this
technique has additional potential benefits such as profound attenuation of the
neuro-endocrine stress response and thoracic cardiac sympathectomy12. There
are indications that an epidural-based anesthetic technique results in superior
analgesia and haemodynamic stability compared to a remifentanil based tech-
nique13. However, the simultaneous effects of these fast-track anesthetic tech-
niques on both the neuro-endocrine and the immunological component the
surgical response have not been studied. Therefore, our first research question
was: “How does the choice of anesthesiological techniques affect homeostatic
responses to fast track coronary artery bypass surgery?”
Another development in health care is that there are increasingly less restric-
tions regarding age and comorbidity in surgical patients. This has resulted in an
increased incidence of coronary artery disease, an important risk factor for
myocardial ischemia, in surgical patients14. Currently, the most important
strategy to decrease the risk at myocardial ischemia in these patients is to
suppress the stress response to surgery . However, many basal questions in rela-
tion to this strategy are still unanswered.We decided to focus at pharmacological
modulation of the autonomic nervous system and the associated cardiovascular
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effects. This resulted in two research questions which were studied in dogs
because this species allowed for detailed measurements in a controlled experi-
mental setting and because our laboratory has extensive experience with cardio-
vascular studies in dogs.
First, there is uncertainty regarding the exact pathophysiology of postopera-
tive myocardial ischemia. Postoperative myocardial ischemia may result from
myocardial oxygen supply-demand mismatch or from thrombosis on coronary
plaques. It is generally believed that sympatholytic therapy may decrease
myocardial ischemia purely from its effect on myocardial oxygen supply-
demand balance. However, this remains unknown from clinical studies because
in these studies it cannot be excluded that sympatholytic therapy reduces
myocardial ischemia by decreasing shear stress on plaques8. Therefore, our
research question was: “Has pharmacological sympatholysis the potential to
decrease myocardial ischemia during emergence from anesthesia purely from its
effect on myocardial oxygen balance?”
The next question was related to choosing the optimal drug for modulation
of autonomic nervous system. The American Heart Association advices to use
either beta-adrenergic antagonists or alpha2-adrenergic receptor agonists for
perioperative pharmacological sympatholysis15. These are fundamentally
different classes of drugs. The principal action of beta-adrenergic blockade is to
decrease beta-adrenoreceptor signalling at the end-organ receptor level.Alpha2-
agonists lower central sympathetic tone via activation of alpha2-receptors in the
medullary dorsal motor complex and in the nucleus tractus solitarius. However,
few studies concentrated on differences between both classes of sympatholytic
drugs. Therefore we studied differences between beta-blockers and alpha2-
agonists on myocardial oxygen demand and on autonomic nervous system
mediated cardiovascular control. This is because these two variables seem to
have an important role in the anti-ischemic effects of sympatholytic drugs.
In summary, the following three research questions have been addressed in this
thesis:
1. How does the choice of anesthesiological techniques affect homeostatic
responses to fast track coronary artery bypass surgery?
2. Has pharmacological sympatholysis potential to decrease myocardial
ischemia during emergence from anesthesia purely from its effect on
myocardial oxygen balance?
3. Do fundamentally different classes of sympatholytic drugs have different
effects on:
A. Myocardial oxygen demand?
B.Autonomic nervous system mediated cardiovascular control mechanisms?
INTRODUCTION
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Overview of the thesis
We started with an overview of the literature on anesthesiological strategies to
decrease myocardial ischemia associated with the stress response to surgery
(chapter 2).
The first research question has been addressed in chapter 3. In this chapter
we compare the effects of two different anesthetic techniques on the inflamma-
tory and the sympathetic stress response after fast-track coronary bypass surgery.
We studied an epidural-based fast track technique and a technique based on the
short-acting opioid remifentanil.
To answer our second research question we applied a critical coronary
stenosis in dogs that were instrumented for detailed measurements of myocar-
dial oxygen balance. Then either a sympatholytic drug (the alpha2-agonist
dexmedetomidine) or a placebo drug was infused and the dogs were allowed to
emerge from anesthesia. Myocardial lactate release was measured as a gold stan-
dard indicator of myocardial ischemia (chapter 4).
The short acting beta1-blocker esmolol and the alpha2-agonist dexmed-
etomidine were compared to study our third research question. The effects of
both classes of sympatholytic drugs on changes in myocardial oxygen demand
and in cardiovascular variables were measured both in absence (chapter 5) and
in presence of a sympathetic stimulus (chapter 6). A selective decrease in
carotid artery pressure from bilateral carotid artery occlusion was used as a
sympathetic stimulus. Differences in the effects of esmolol and dexmede-
tomidine on autonomic nervous system function and associated hemodynamic
stability have been studied in chapter 7. Autonomic nervous system tone and
baroreceptor mediated cardiovascular control was evaluated from; the power of
frequency spectra of heart rate and aortic pressure variability, plasma
norepinephrine concentrations, the response to a decrease in carotid artery pres-
sure, and cardiac baroreflex sensitivity. Our findings are discussed and sugges-
tions for future research are proposed in chapter 8. Finally, the previous
chapters are summarized in chapter 9.
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CHAPTER 2
The anesthesiologist and optimising cardiac
outcome: Strategies to modulate the perioperative
stress response
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Perioperative myocardial ischemia, a serious problem
Cardiac complications are a major cause of morbidity and mortality after
surgery1. Early postoperative myocardial ischemia is the most important
predictor of these cardiac complications, increasing their relative risk 9 to 21
times. It is important to realize that myocardial ischemia and cardiac complica-
tions constitute a continuum of biological processes.With a shortage of myocar-
dial oxygen supply, anaerobic glycolysis replaces oxidative phosphorylation as
the primary source for ATP. This results in an increase in lactate, ADP, AMP,
glucose-6-phosphate, and fructose-6-fosphate.After one minute the function of
the ischemic area starts to deteriorate proportionally to the decrease in myocar-
dial blood flow2. Thereafter electrophysiological abnormalities start as reflected
by ECG changes. Irreversible myocardial damage (i.e. myocardial infarction)
occurs after approximately 30 minutes cessation of myocardial blood flow.
Congestive heart failure and cardiac death may result from changes in myocar-
dial function and electrical stability during or after this process.
The incidence of myocardial infarction is approximately 0.06% in one
month in a population-based cohort of men and women aged 55 years and
older3. In contrast, the incidence of in-hospital myocardial infarction after
surgery varies between 1.4% in relatively unselected patients, and 5.6% in
cardiac risk patients4. These figures suggest that surgery increases the risk for
myocardial infarction more than ten-fold. Why is this?
The stress response to surgery
The most important reason for the increased incidence of myocardial infarction
after surgery is related to the stress response associated with tissue trauma. This
response incorporates profound immunological and neuro-endocrine changes
with the ultimate goal to restore tissue homeostasis. A simplified picture of this
response and its feedback mechanisms is shown in fig. 1.
The immunological part of the surgical stress response starts as a tissue based
reaction to trauma and is designed to decrease infections and promote healing.
As far back as AD 40, Celsus defined this response as rubor, calor, dolor, and
tumor.Currently we know that this response includes complex cascades, such as
the complement, cytokine, and the coagulation-fibrinolytic cascades, and
changes in cellular components of the immune system.
The cytokine cascade is of key importance and starts with the release of the
cytokines IL-1 and TNF-α from activated macrophages and monocytes in
injured tissue5. These cytokines stimulate the release of IL-6 which is mainly a
pro-inflammatory cytokine and responsible for inducing the production of
CHAPTER 2
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acute phase proteins such as C-reactive protein, fibrinogen and α2-macro-
globulin in the liver. These acute phase proteins act as inflammatory mediators
and as anti-proteinases, and promote tissue repair. To prevent a systemic overre-
action of this pro-inflammatory response, tissue trauma also stimulates the
production and release of anti-inflammatory cytokines such as IL-10, IL-1ra,
and TNF soluble receptors. There are indications that it is this balance, between
pro- and anti-inflammatory cytokine responses,which is most important for the
clinical prognosis after surgery6. Closely interconnected with this cytokine
cascade are changes in the coagulation-fibrinolytic cascades7. Proinflammatory
cytokines increase the expression of tissue factor and of intravascular leukocyte
OPTIMISING CARDIAC OUTCOME
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Figure 1. Some of the hormonal and neural pathways involved in the neuro-endocrine and the
immunological response to tissue injury . TNF: tissue necrosis factor; IL-1: interleukine-1; IL-6:
interleukine-6.
adhesion molecules, activate the endothelium, and stimulate the production of
platelet activation factors. Also, the fibrinolytic and protein-C anticoagulant
pathways are down regulated.As a result, the immune response to tissue injury is
associated with a marked procoagulant state.
The immune response to tissue injury also includes profound changes in the
cellular components of the immune system. There is an immunoconversion
from the acquired immune response to the natural immune response8. This
increased activity of the natural immune system assures the highest level of host
defence because it is capable of instantaneously attacking pathogenenic agents
and detecting infected and injured cells. The down-side of this immuno-
conversion manifests as anergy in response to skin testing and failure to produce
specific antibodies.Theoretically, this may result in an increased risk of sepsis and
increased metastatic tumour spread after surgery9,10.
The neuro-endocrine part of the surgical stress response is a central nervous
system mediated response. It peaks early after surgery, when the effects of anes-
thesia wear off. Its magnitude and duration are influenced by factors such as the
amount and location of tissue damage,pain, anxiety, infection,hypovolemia, and
hypoxemia.The most important function of the neuro-endocrine response is to
promote an adaptive redirection of oxygen and nutrients to the stressed body
sites and the central nervous system11. Additionally, it has a role in preventing an
overreaction of the immune response. Neural and cytokine signalling of tissue
trauma results in activation of the paraventricular nucleus of the hypothalamus.
The increase in hypothalamic releasing factors in turn stimulate the pituitary to
release vasopressin, growth hormone, prolactin and propiomelanocortin.
Propiomelanocortin is metabolised to ACTH,which stimulates the secretion of
corticosteroids, and to beta-endorphin, an endogenous opioid. Hypothalamic
activation also changes the activity of autonomic nervous centra towards an
increased sympathetic tone and a decreased parasympathetic tone. Clinical
consequences are:1) down-regulation of the beta-adrenoreceptor system related
to increased plasma concentrations of catecholamines and 2) a decrease in vagal
mediated heart rate variability in patients after major surgery12. In this way
changes in autonomic nervous balance may explain increased blood pressure
fluctuations after surgery13
The immunological and the neuro-endocrine parts of the stress response are
no separate entities. Instead, the system is designed as a neuro-endocrine-
immune feedback loop which allows regulation of host defence mechanisms14-
18. For example, immune mediators and cytokines activate the neuro-endocrine
stress response because they can pass the blood-brain barrier and because they
can stimulate vagal and sensory afferent nerves19. Simultaneously,
glucocorticoids and catecholamines activate receptors on immune cells which
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results in a negative-feedback control of the immune response. The dynamic
nature of mediators of the stress response adds to the complexity of the stress
response. For example, the actions of some cytokines switch from pro-inflam-
matory to anti-inflammatory, depending on timing and context16.
In conclusion, surgery leaves the patient with much more than a tissue scar.
Studies focussing on homeostatic responses to tissue injury continue to reveal
the enourmous complexity of these responses. It is this increase in basic knowl-
edge on homeostatic responses which offers exciting opportunities to increase
our knowledge on the relation between homeostatic responses and
perioperative morbidity.
Linking the surgical stress response to myocardial ischemia
The atherosclerotic coronary plaque is the common morphological risk factor
of perioperative myocardial ischemia and infarction. Over the past decade we
have learned that the immune response occupies a central position in the
pathophysiology of these plaques20. We have also appreciated the dynamic
nature of inflammatory-immune processes in these plaques which may be
divided into two extremes. At one end of the spectrum is the structural vulner-
able plaque, which has a central lipid core, many inflammatory cells and a thin
cap. At the other end of the spectrum is the stable plaque which has few inflam-
matory cells and a thick fibrous cap.
Parallel to this variability of inflammatory-immune processes in plaques the
aetiology of perioperative myocardial infarction may be divided into the
following two common mechanisms21 (Fig. 2).
First, myocardial infarction may result from thrombosis on, or rupture of,
coronary plaques. Potential triggers of this mechanism are: increased systemic
inflammatory and procoagulant activity, increased sympathetic mediated shear
stress on plaques, and increased sympathetic or local mediated coronary
vasoconstriction. This mechanism accounts for less than 50% of perioperative
myocardial infarctions and the timing of these infarctions has no specific corre-
lation to the end of surgery.
Another mechanism for perioperative myocardial infarction is prolonged
myocardial oxygen supply-demand mismatch in the presence of severe, but
stable, coronary stenosis. The postoperative increase in sympathetic tone seems
to be central to this type of myocardial infarction. Myocardial oxygen demand
may increase from associated increases in heart rate, arterial pressure, and
myocardial contractility. Simultaneously, myocardial oxygen supply may
decrease from coronary vasoconstriction and a decreased diastolic filling time.
These changes in myocardial oxygen demand and supply may result in
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subendocardial ischemia, and if prolonged, in circumferential myocardial infarc-
tion. Typically, this ST-depression type of myocardial ischemia occurs within 8
to 24 hours from the end of surgery, and the peak incidence of associated cardiac
death is in the first 1-3 postoperative days.
However, although these two pathophysiological mechanisms are clearly
associated with perioperative myocardial infarction, the exact mechanism of
perioperative myocardial ischemia remains unknown. To date, it remains
unknown if myocardial infarction can result purely from mismatches in myocar-
dial oxygen supply and demand. This is because the coronary plaque is the
common morphological lesion in patients having perioperative myocardial
infarction. Rupture of, and thrombosis on, coronary plaques may resolve spon-
taneously and therefore it can never be excluded that this mechanism contrib-
uted to the etiology of perioperative myocardial infarction. Another problem in
studying the pathophysiological mechanisms of perioperative myocardial infarc-
tion is that methodological limitations prevent accurate measurement of
myocardial oxygen consumption and demand. Finally, the diagnosis of myocar-
dial ischemia and infarction is very difficult. Selecting ST-segment changes as an
outcome measure may not always be clinically relevant because they also result
CHAPTER 2
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Figure 2. Two common pathophysiological mechanisms of perioperative myocardial infarction.
These are;1) long-term mismatch in myocardial oxygen demand and supply in presence of a severe
stable coronary artery stenosis and,2) rupture and thrombosis in presence of an unstable coronary
plaque. Adapted with permission from Libby et al (Circulation 2005; 111: 3481-8.)
from changes in temperature, serum electrolytes, position of electrodes, and
from administration of drugs22. A more precise measure of myocardial ischemia,
but difficult to obtain in patients, is the presence of lactate release from the
myocardial area at risk. For the diagnosis of myocardial infarction several combi-
nations of criteria such as typical ischemic chest pain, typical ECG findings, and
increases in plasma concentrations of biochemical markers of myocardial injury
are used. However, chest pain is often masked by analgesics in patients recov-
ering from surgery and there is no generalised accepted standardization of these
criteria1.
It is likely that both inflammatory mediated coronary thrombotic events and
sympathetic mediated mismatches in myocardial oxygen balance contribute to
myocardial infarction in the perioperative period. This implicates that
multimodal strategies are needed to decrease the incidence or severity of
perioperative myocardial infarction.
Strategies to decrease the surgical stress response
The surgeon may decrease the immunological response to tissue injury by
further developing surgical techniques with lesser tissue trauma.However, these
techniques seem to have relatively little effect on the neuro-endocrine
response23. Also, there seems to be no immunologic advantage of laparoscopic
surgery in relatively uncomplicated operations such as inguinal herniorrhaphies
and in advanced procedures such as colectomies24.
The anesthesiologist may decrease the neuro-endocrine response to surgery
by carefully choosing anesthetic strategies. In contrast to earlier beliefs, there are
recent indications that these techniques also affect the immune response to
surgery25.Anesthetic strategies may affect the immune response to surgery indi-
rectly by modulating the neuro-endocrine response or directly by affecting the
functions of immune competent cells. In addition to choosing anesthetic strate-
gies, the anesthesiologist may implement pharmacological strategies to modu-
late the perioperative stress response. Of these, sympatholytic drugs receive most
attention because of their potential to decrease cardiac complications.
1. Anesthetic and analgesic strategies to decrease the surgical stress response.
In general, either an epidural based or an opioid based anesthetic strategy may
be used to decrease the stress response to major surgery.
Epidural anesthesia and analgesia
Epidural analgesia involves the administration of local anesthetics through a
catheter placed in the epidural space thus interrupting peripheral nerve traffic.
The level of the cathetertip and the infusion rate of local anesthestics determine
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the extend and spinal level of nerve blockade. Epidural analgesia has profound
sympatholytic effects because it decreases the afferent neural input from the site
of injury and because it may decrease the efferent neural input to the adrenal
gland. Additionally, epidural anesthesia may also suppress the response of the
hypothalamic-pituitary-adrenal (HPA)- axis to surgical stress. However, this
suppression of the HPA axis applies mainly to patients having surgery below the
umbilicus. In high abdominal and thoracic surgery epidural analgesia does not
consistently suppress the HPA-axis response. The reason for this is unknown,
but afferent neural input may not be blocked adequately or the inflammatory
response may have an important role in activation of the HPA-axis in this type
of surgery26.
The cardiovascular effects of epidural anesthesia depend on the extend and
level of epidural blockade and associated sympatholysis27. The heart is
innervated by sympathetic nerves from thoracic level 2 to 4.Blockade of cardiac
sympathetic fibers associated with a high level epidural block (above the fifth
thoracic level) may therefore decrease myocardial oxygen demand. Additionally,
the diameter of stenotic coronary arteries and the endo- to epicardial blood flow
ratio may increase as a result of a decrease in sympathetic mediated coronary
vasoconstriction. In contrast, during lumbar epidural anesthesia a reflex
compensatory increase in thoracic sympathetic nerve activity may compromise
myocardial oxygen balance.
In addition to these neuro-endocrine effects there are indications that
epidural techniques also modulate the immunological response to surgery. This
seems to be an indirect effect because epidural infusion of local anesthetics
alone, in the absence of surgery, seems to have only transient and minor effects
on human immune function28. In contrast, in presence of surgery epidural anes-
thesia does have immunological effects. Epidural analgesia decreased IL-6
production after low abdominal surgery29and decreased circulating levels of the
anti-inflammatory cytokine IL-10 in patients having coronary artery bypass30.
Also, epidural analgesia attenuated post surgical lymphocyte depression in
patients having spine surgery31. The exact mechanism of these immunological
effects remains unknown.They may be related to the neuro-endocrine effects of
epidural anesthesia or to direct effects of local anesthetics on neutrophils32.
Clinically, an epidural technique has profound analgetic effects and reduces
many of the potential adverse physiological consequences of surgery. However,
the impact of epidural analgesia on postoperative mortality and morbidity
remains uncertain. In a large randomised controlled trial in high-risk patients
undergoing major intra-abdominal surgery an epidural technique improved
analgesia, and reduced respiratory failure33. However, this trial failed to show an
effect of epidural analgesia on cardiovascular morbidity. Further, it is important
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to realise that potentially serious complications of an epidural technique include
epidural hematoma, epidural abscess, and post-dural puncture headache.
Opioid anesthesia and analgesia
As alternative to an epidural based anesthetic strategy, an opioid based strategy
may be used to modulate surgical stress responses. Opioids exert their effects
through the μ, κ, and δ – opioid receptors which belong to the family of G-
protein coupled receptors. These receptors are present on various cells involved
in the stress response, including central neurons and immune cells.
Opioids modulate neuro-endocrine stress responses because of their analgesic
effects and because of their effects on receptors in the hypothalamus and
brainstem17,34. It has been known for many years that stimulation of μ-opioid
receptors in the hypothalamus suppresses the response of the HPA-axis . Stimu-
lation of central μ-opioid receptors also affects autonomic nervous system
activity.Vagal outflow increases,but variable effects on sympathetic outflow have
been reported. It has been suggested that these effects on sympathetic outflow
depend on which hypothalamic nucleus is stimulated34. In the surgical patient
opioids favour a sympatholytic effect. However, this effect does not seem to be
very strong because high doses of morphine are needed to suppress the increase
in catecholamines during thoracic and upper abdominal surgery35. Also, further
increasing the dose of opioids has no additional sympatholytic effect36.
Opioids also modulate the immunological stress response. This may result
from direct interaction with opioid receptors on cells of the immune system, or
indirectly from their effect on neuro-endocrine stress response. Stimulation of
opioid receptors on immune cells results in a suppression of numerous compo-
nents of the immune system such as natural killer cell activity, neutrophil
complement and immunoglobulin receptor expression, chemokine induced
chemotaxis, and phagocytosis37. Also most clinical studies point toward an
overall immunosuppressive effect and an increased susceptibility to infections of
chronic administration of opioids38.However, the immunological consequences
of short-term opioid analgesia are less clear.
Opioids may have a beneficial effect on cardiac outcome. In a study in cardiac
surgical patients intensive postoperative opioid analgesia decreased the severity
of myocardial ischemia39. Also, there are indications that direct stimulation of
opioid receptors on cardiac myocytes may limit myocardial ischemic injury40.
However, no definite data are available on the effects of opioids on cardiac
outcome.
2. Pharmacological strategies
In addition to choosing anesthetic strategies the anesthesiologist may also
modulate perioperative stress responses by adding drugs. Of these, beta-blockers
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and α2-agonists, two fundamentally different classes of sympatholytic drugs, are
most commonly used .
Beta-blockers
The principle action of beta-adrenergic blockade is to decrease beta-
adrenoreceptor signalling at the end-organ receptor level41. Beta-1 selective
beta-blockers have been used in most studies on perioperative beta blockade.
However, the clinical importance of beta1-receptor selectivity on cardiac
mortality remains to be determined42. Esmolol, a beta-1 selective blocker, has
been advocated for use in the perioperative period because of its extremely
short elimination half-life of approximately 9 minutes43.
In general, beta-blockers seem to have no major effects on the neuro-endo-
crine stress response. They have been found to either increase or to have no
effect on the activity of the sympathetic and parasympathetic nervous system44-
46. These differences in findings may be explained from differences in methods
of measurements, and from differences in route and in duration of the adminis-
tration of the beta-blocker.The effect of beta-adrenergic blockade on the HPA-
response is largely unknown. In a study in healthy adults the beta-blocker
propanolol had no effect on the HPA-response associated with a pentagastrine
induced panic attack47. Also, a study in volunteers showed that the adrenal beta-
receptor plays no major role in steroid secretion48.
There is increasing evidence that beta-adrenergic receptors on immune cells
have a central role in the connection between sympathetic activation and
immune function49. However, there are very few studies focussing on the
immunological effects of beta-blockers. In studies in mice beta blockade
changed cellular immune functions and reduced survival from septic or hemor-
rhagic shock50 51,52.
The effect of perioperative beta-blockade on cardiac outcome has been
intensively studied. Mangano and colleagues showed that perioperative atenolol
administration decreased long term overall mortality by 55% and cardiac
mortality by 65% in patients having or being at risk for coronary artery disease
and undergoing major surgery53. Poldermans and colleagues showed in a
placebo controlled study that bisopropol significantly decreased perioperative
cardiac morbidity and mortality in a very high cardiac risk group54. Based on
this evidence the American Heart Association guidelines strongly support the
perioperative use of beta-blockers in patients having an increased cardiac risk55.
However, there are also indications that this evidence is too optimistic. In the
study of Mangano and colleagues the in-hospital deaths were excluded, beta-
blockers were stopped in the control group, and there were more diabetic
patients in the control group. The study of Poldermans and colleagues has been
criticized for the lack of blinding and the implausibly large treatment effects.
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More recent trials did not demonstrate any benefit from perioperative beta-
blocker therapy56. Very recently, a meta-analysis of 69 controlled trials showed
that beta-blockers reduce myocardial ischemia,but have no effect on myocardial
infarction or mortality57.
The exact mechanism by which beta blockers reduce myocardial ischemia
remains unknown21. In general, suppression of sympathetic beta-receptor medi-
ated cardiovascular responses is believed to be their most important anti-
ischemic mechanism. In this way beta-blockers may prevent prolonged, stress
induced mismatches in myocardial oxygen balance. More specifically, there is
quite convincing evidence that the protective effect of beta blockers is related to
their heart rate lowering effect. Controlling the heart rate below the individual
ischemic threshold for 48 hour after surgery reduced myocardial ischemia in
patients at high risk of cardiac complications58. Also, high doses of beta-blockers
and tight heart rate control were associated with reduced perioperative myocar-
dial ischemia and troponin-T release in vascular surgery patients59.
Alpha
2
-agonists
The principal action of alpha2-agonists is to decrease central sympathetic
outflow. Other well-documented effects of alpha2-agonists include anxiolysis,
sedation, and analgesia.Clonidine is the prototypical alpha2-agonist to which all
other alpha2-agonists are compared, and has been used for more than 40 years in
treatment of hypertension and in opioid and alcohol withdrawal syndromes.
The alpha2-agonist dexmedetomidine is very selective for alpha2-receptors
(dexmedetomidine: α2 / α1 selectivity: 1600, versus clonidine: α2 / α1 selec-
tivity: 40) and its shorter plasma half live makes titration to effect more
easy(dexmedetomidine plasma half life:2 hours,versus clonidine plasma half life:
9 hours). In 1999 the US Food and Drug Administration approved
dexmedetomidine for sedation of intensive care patients. Since that time the
number of studies focussing on this drug has increased enormously. A recent
study in human volunteers showed that dexmedetomidine has a profound
sympatholytic effect which is already clinically significant at the lowest plasma
concentration60.
Alpha2-agonists affect mainly the autonomic nervous system mediated effects
of the neuro-endocrine stress response. They lower central sympathetic tone via
activation of alpha2-receptors in the medullary dorsal motor complex and in the
nucleus tractus solitarius. These central sympatholytic effects of alpha2-agonists
are augmented by inhibition of peripheral ganglionic transmission61. Addition-
ally, there are indications that alpha2-agonists enhance parasympathetically
mediated heart rate control from their effects on alpha2-receptors in the vagal
nuclei of the medulla oblongata62. A recent study demonstrated the clinical
importance of central alpha2-receptors on autonomic responses to stress
63. It
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showed that persons which have a genetic polymorphism of the central alpha2-
adrenergic receptor have an increased autonomic responsiveness to various
stressors. In addition to their direct sympatholytic effects, alpha2-agonists may
decrease sympathetic responses from their analgetic, anxiolytic, and sedative
effects. These effects are mediated by stimulation of alpha2-receptors in the
locus coeruleus and nucleus reticularis lateralis. In contrast to their profound
autonomic nervous system effects, alpha2-agonists do not seem to have an
important effect on the HPA-axis mediated effects. Clonidine did not affect
cortisol release in patients undergoing pancreatico- biliary surgery64or CABG
surgery65. Also, dexmedetomidine infusion had no effect on serum cortisol or
ACTH concentrations after major surgery66.
There are few data on the immunological effect of alpha2-agonists. In an in
vitro study, clonidine and dexmedetomidine did not affect chemotaxis,
phagocytosis, or superoxide production by human neutrophils67. The immuno-
logical effects of alpha2-agonists in the presence of surgery are equivocal.
Clonidine reduced the interleukin-6 production in response to total abdominal
hysterectomy68. In contrast, clonidine had no effect on the IL-6 response after
pancreatico- biliary surgery64. Also, a postoperative sedative infusion of
dexmedetomidine had no significant effects on IL-6 plasma concentrations66. A
study focussing on the cellular immunological response of clonidine after
CABG surgery showed that this alpha2-agonist changed the T-lymphocyte
subpopulation in favour of a pro-inflammatory response69.However, the clinical
relevance of these data remains to be determined.
Alpha2-agonists have been less well studied than beta-blockers for
perioperative myocardial protection;6 versus 11 randomized controlled trials up
to November 200270. The potential benefit of alpha2-agonists on myocardial
ischemia was initially controversial because of their direct coronary vascular
effects. Alpha2-agonists may jeopardize coronary flow reserve from stimulation
of vascular smooth muscle alpha2B-receptors
71. However, activation of alpha2-
adrenoreceptors on vascular endothelial cells may cause vasodilatation. Also,
multiple clinical studies and two meta-analyses have shown that alpha2-agonists
decrease perioperative myocardial ischemia in cardiac risk patients72,73. In the
largest study this beneficial effect resulted mainly from the effect of an alpha2-
agonist in a subgroup of patients with known coronary heart disease and under-
going vascular surgery74. Recently, a prospective double blind trial in 190
patients showed that clonidine reduces perioperative ischemia and postoperative
mortality in patients undergoing non-cardiac surgery and having or being at
risk for coronary artery disease75.
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It is important to realise that studies on the effect of an intervention on the stress
response are very difficult to interpret.Firstly, this is because the stress response is
part of a feedback system. Another difficulty is that there is a paucity of basal
data on “normal” quantitative relationships between the type and duration of
stressor and sequential changes in plasma concentrations of mediators of the
stress response76. Studies having perioperative myocardial ischemia or myocar-
dial infarction as an outcome measure are even more difficult to interpret. This
is because these outcome measures are difficult to diagnose and have a low inci-
dence1. It has been calculated that more than 6000 patients are needed to detect
an effect of an intervention on myocardial infarction77.
In conclusion, anesthesiological strategies and sympatholytic pharmacological
strategies have the potential to decrease perioperative myocardial ischemia.Also,
all of these strategies seem to affect both the immune and the neuro-endocrine
component of the stress response. However, these strategies have different loca-
tions of action within the pathways of the stress response (fig. 3). This seems to
result in important qualitative and quantitative differences in their potential to
modify various components of the stress response (table 1).
Different strategies to modulate the perioperative stress
response: comparative studies
It is important to focus on differences between the various stress modulating
strategies because this knowledge may help to define the optimal strategy for an
individual patient. For example, a patient at risk for developing an excessive
inflammatory response after surgery may benefit from a strategy which is known
to reduce this inflammatory response. With the exception of studies comparing
epidural based to opioid based strategies, there is a paucity of comparative data
on how various strategies affect different components of the stress response
(Table 2).From these data a speculative ranking can only be made for the poten-
tial of the various strategies to decrease sympathetic outflow: Epidural > alpha2-
agonist > opioid > beta-blocker.Below we will discuss differences of frequently
used anesthesiological and sympatholytic strategies into more detail.
Differences in modulation of the stress response of two important
anesthesiological strategies
Differences between the neuro-endocrine effects of an epidural based and an
opioid based anesthetic technique have been studied extensively78,79. Collec-
tively, the available studies indicate that an epidural-based technique reduces
sympathetic and cortisol responses more effectively than an opioid technique,
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Figure 3.Strategies to decrease the stress response to tissue injury and their main location of action
within the pathways of the stress response. 1: opioids; 2: alpha2-adrenergic agonists; 3: epidural; 4:
beta-adrenergic antagonist.TNF:tissuenecrosis factor;IL-1:interleukine-1;IL-6:interleukine-6.
Table 1. General effect of different strategies on various components of the surgical stress
response. ↓: decrease; ↑: increase; ↔ : no effect; ?: unknown because of very few studies.
Thoracic
Epidural
Opioid Beta blocker Alpha2-
agonist
Sympathetic outflow ↓ ↓ ↑ ↓ ↑ ↔ ↓
Parasympathetic outflow ↔ ↑ ↑ ↑ ↔ ↑
HPA-axis hormones ↓ ↔ ↓ ↔ ↔
Activity immune cells ↑ ? ↓ ↓ ? ?
especially in surgery below the umbilicus. However, less data are available on
immunological differences between these two techniques. Epidural analgesia
seems to maintain postoperative lymphocyte function better than opioid anal-
gesia29,31.However,no effect of epidural analgesia on the IL-6 response has been
found26,30,80. There are tight feedback connections between the immunological
and neuro-endocrine components of the stress response. Therefore, it seems
logical to study the effect of an intervention on both components of the stress
response. However, most studies concentrate on only one of these components.
The short-acting opioid remifentanil is increasingly used since the introduction
of fast track surgical programs. These programs aim at shortening recovery time
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Table 2 . Studies in which the effects of different strategies on the stress response are directly
compared
Neuro-endocrine response Immune response
Epidural vs opioid Epidural suppresses sympathetic and cortisol
response more effectively78,79
Epidural maintains lymphocyte
function after surgery better
than opioid29,31.
Epidural has no effect on IL-6
response26,30,80
Alpha2-agonist vs
beta-blocker
α2-agonist suppressed the increase in plasma
catecholamines to intubation85 and to a rapid
increase in desflurane86 more than the beta-
blocker. Cortisol response: not determined
Not determined
Epidural vs alpha2-
agonist
Addition of epidural analgesia decreased
plasma epinephrine concentrations compared
to addition of clonidine in patients having
CABG surgery65. Cortisol response: not
different.
Not determined
Epidural vs
beta-blocker
Addition of epidural anesthesia to beta-
blocked patients suppressed the increase in
myocardial oxygen consumption related to
surgery87. A high thoracic epidural decreased
angina pectoris in beta-blocked patients88.
Cortisol response: not determined
Not determined
Opioid vs
alpha2-agonist
In CABG surgery the addition of clonidine
to a general anesthetic resulted lower plasma
catecholamine levels compared to a high dose
opioid regimen89. Cortisol response: not
determined
Not determined
Opioid vs
beta-blocker
Opioids suppressed the neuro-endocrine
stress response to laryngeal stimulation more
profoundly than beta-blockers90,91. Cortisol
response: not determined
Not determined
and therefore incorporate the use of short-acting anesthetic drugs or the combi-
nation of a regional anesthetic technique with a low dose general anesthetic.
The fear is that these techniques thus may leave the patient relatively unpro-
tected from potential harmful stress responses during the early period after
major surgery81. Recently, it has been shown that an epidural-based anesthetic
technique results in superior analgesia and haemodynamic stability compared to
a remifentanil based technique82.
Differences in modulation of the stress response of two pharmacological
sympatholytic therapies.
Only a few studies have compared the effects of an alpha2-agonist and a beta-
blocker on the neuro-endocrine stress response and the related cardiovascular
effects. This is surprising because it is very likely that these fundamentally
different classes of sympatholytic drugs have different effects on the neuro-
endocrine stress response. Alpha2-agonists have a central sympatholytic effect,
thus decreasing both alpha- and beta-receptor mediated sympathetic effects. In
contrast, beta-blockers decrease only beta-receptor mediated sympathetic
effects. Knowing differences between both classes of drugs on autonomic
nervous system mediated cardiovascular control is important. This is because of
its relation to myocardial oxygen balance and because evidence has emerged
that cardiovascular control as such may be important in decreasing cardiac
complications83. An example of this evidence is that heart rate variability, one of
the indicators of impaired cardiovascular control, is an independent predictor of
adverse cardiac outcome in certain groups of patients84. The few comparative
studies on the neuro-endocrine effects of alpha2-agonists and beta-blockers
showed that the alpha2-agonist clonidine suppressed the increase in plasma cate-
cholamines to intubation85 and to a rapid increase in desflurane86 more than the
beta-blocker esmolol. However, to date, differences in parasympathetic nervous
system activation and baroreceptor mediated cardiovascular control of these
groups of drugs have not been studied.
To conclude, the stress response to surgery consists of an immunological
component and a neuro-endocrine component which interact closely. Each of
these components seems to be involved in increasing the risk at perioperative
myocardial ischemia. The anesthesiologist has a pivotal role in modulating the
stress response to surgery and thus decreasing the risk at perioperative myocar-
dial ischemia. To this, several anesthesiological techniques and pharmacological
sympatholytic therapies may be used. There are indications that these various
options affect the perioperative stress response differently.Knowing these differ-
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ences may help to define the optimal stress response modulating strategy.
However, these differences and the associated cardiovascular effects are largely
unknown because they have not been studied into detail. The studies presented
in this thesis were designed to fill parts of these gaps in our knowledge.
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Abstract
Background and objective. Epidural-based and remifentanil-based anaesthetic
techniques have different effects on the haemodynamic and analgetic responses
after cardiac surgery. The purpose of this study was to compare their effects on
sympathetic and inflammatory responses during the first day after surgery.
Methods. Patients received propofol anaesthesia combined with either
thoracic epidural anaesthesia and low dose remifentanil (TEA group) or with
high dose remifentanil (REMI group). Postoperative analgesia consisted of
epidural bupivacaine and morphine (TEA group) or intravenous piritramide
(REMI group).
Results. Plasma catecholamines and the pro-inflammatory interleukin-6 (IL-
6) were measured as measures of sympathetic and inflammatory responses
respectively. Additionally, bactericidal permeability increasing protein,
lipopolysaccharide binding protein, and C-reactive protein, and white blood
cell count were measured. Ventilator dependency and analgesia were also evalu-
ated. Plasma concentrations of epinephrine were less in the TEA group
compared to the REMI group (300 (100 – 1300) versus 1000 (600 – 1600) pmol
L-1,median (interquartile range), P < 0.05) during the first 4 hours after surgery.
In contrast, release of IL-6 was less in the REMI group (140 (100 – 290) versus
(400 (200 – 500) pg ml-1, P < 0.05). Analgesia was superior and ventilator
dependency shorter in the TEA group. All other variables were not different.
Conclusions. The epidural-based anaesthetic technique had a superior
sympatholytic effect and was associated with an increased IL-6 response, indi-
cating the immunologic modulatory effects of anaesthesia management.
Keywords. Epidural, immune response, surgery – cardiovascular, opioid, sympa-
thetic nervous system.
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Introduction
Recently, there has been much discussion about the safety of fast track cardiac
anaesthesia because it may leave the patient relatively unprotected from poten-
tial harmful homeostatic stress responses during the early postoperative period
[1]. Traditionally, there was much attention for the neuro-endocrine responses
to cardiac surgery, which resulted in the concept of high-dose opioid anaes-
thesia. Over the past decades there is increasing interest in modulating the
immune response to cardiac surgery with the expectation to decrease postoper-
ative complications such as the systemic inflammatory response syndrome and
infections [2].
Several different fast track anaesthetic strategies for cardiac surgery have been
described. One is a technique based on the short-acting opioid remifentanil,
which allows for the intra-operative use of high dose opioids without delaying
extubation [3]. Alternatively, a thoracic epidural-based anaesthetic technique
can be used because this technique has additional potential benefits such as
profound stress response attenuation and thoracic cardiac sympathectomy [4].
Recently, it has been shown that an epidural-based anaesthetic technique results
in superior analgesia and haemodynamic stability compared to a remifentanil
based technique [5]. However, to our knowledge, studies comparing the early
postoperative neuro-endocrine and the immunological effects of these two
techniques are lacking. Therefore, we prospectively studied indicators of these
homeostatic stress responses in patients managed with either an epidural-based
or a remifentanil-based fast-track technique during the first day after elective
on-pump coronary artery bypass surgery (CABG).
Methods
After local ethics committee approval and written informed consent from the
patients, 30 adult patients undergoing elective on-pump CABG were allocated
to this prospective trial.The sample size was chosen on the basis of power calcu-
lation from a pilot study. It was calculated that a sample size of 15 in each group
would provide 80% power using a Student’s t-test with a significance level of
0.05 for detecting a difference in IL-6 and in catecholamines of at least 100%.
The current trial consisted of the following two anaesthetic treatment groups; 1)
Thoracic Epidural Analgesia (TEA group), 2) high dose remifentanil (REMI
group). Exclusion criteria included left ventricular ejection fraction less than
25%, recent myocardial infarction, pre-operative inotropic or intra-aortic
balloon pump support, and significant pulmonary,endocrine, renal,or neurolog-
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ical disease. Patients who were not suitable for epidural blockade according to
our National Guidelines were also excluded.
Experimental design
All patients continued their usual medications and received standardized
premedication with oral midazolam 0.1 - 0.2 mg kg -1. After arrival in the
induction room, the radial artery was cannulated and blood was sampled for
baseline (BL) measurements. In the TEA group, the epidural catheter was
inserted more than one hour before surgery at the C7 - T1 level. It was tested
with 2 ml of lidocaine 2%. A loading dose of 10 ml bupivacaine 0.25% and 2.5
mg morphine was infused over 1 hour, and sensible block heights were tested
with application of cold. Anaesthesia was induced using target-controlled infu-
sion (TCI) of propofol with the target at 2 μg ml-1 (BD Master Diprifusor TCI
system, Brezins, France), remifentanil (GlaxoSmithKline, Zeist, The Nether-
lands) 2.5 μg kg -1 in 4 minutes, and pancuronium 0.1 mg kg –1 to facilitate
orotracheal intubation. The patients were ventilated with oxygen-enriched air
(40% oxygen) and a pulmonary artery catheter was inserted into the right
internal jugular vein.Anaesthesia was maintained with TCI propofol (target 1-2
μg ml-1) and a remifentanil infusion protocol, which was different for both
groups (REMI group 0.5 μg kg-1 min-1, TEA group 0.125 μg kg-1 min-1).
Additionally, an epidural infusion of bupivacaine [3.75 mg ml-1] and morphine
[0.2 mg ml-1] was started at a rate of 1.5 ml hour-1 in the TEA group.
Cardiopulmonary bypass was standardized and performed using a hollow fibre
membrane oxygenator, haemodilution, and moderate hypothermia (34 °C).
At arrival in the intensive care unit (ICU) patients were kept sedated with
propofol (0.5 mg kg-1 h-1) and remifentanil (0.025 μg kg-1min-1) for four hours.
If necessary,propofol was increased to achieve moderate sedation (Ramsay seda-
tion score 3-5) [6]. Acetaminophen, 1 gram every 6 hours was started as a basic
analgesic. In the TEA group bupivacaine 0.125% and morfine 0.2 mg ml-1 were
infused into the epidural catheter at a rate of 1.5 ml h-1 for 48 hours.The REMI
group received 0.15 mg kg–1 intravenous piritramide, a μ-receptor agonist with
a potency of 0.7 compared with morphine, 15 minutes before stopping the
sedative infusion. Tracheal extubation was performed when the patients had
stable haemodynamics, were normothermic (core temperature > 36.5ºC), not
bleeding (chest tube drainage < 100 mL h -¹), and had adequate spontaneous
ventilation (tidal volume > 5 mL kg -¹, respiratory rate > 10 breaths min -¹,
minute ventilation > 90 mL kg -¹ min -¹,FiO2 < 40%,peak end-expiratory pres-
sure < 5 cm H2O, and arterial PO2 > 12 kPa). Time to extubation from stop
sedation was recorded.
The nursing staff evaluated pain scores every 30 minutes on a 5-point scale
from “no pain” to “very severe pain” after stopping the sedative infusion.
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Piritramide 0.3 mg kg -¹ was injected intramuscularly as an escape analgesic if
the patient had more than slight pain. Quality of postoperative analgesia was
evaluated from the number of piritramide administrations during the first 18
hours in the ICU. Then the patients were discharged to a step-down unit.
Plasma Sampling and Measurements
Plasma concentrations of catecholamines (norepinephrine and epinephrine)
were measured as indicators of sympathetic tone, and interleukin-6 (IL-6) as a
key mediator in the inflammatory response. Additionally, we measured bacteri-
cidal permeability increasing protein (BPI), as an indicator of neutrophil activa-
tion, lipopolysaccharide binding protein (LPB) and C-reactive protein (CRP) as
indicators of the acute phase response, and leukocyte numbers and percentage of
lymphocytes as indicators of the immunological cell response.
Samples for measurement of catecholamines and of BPI, LPB, and IL-6 were
taken at five time-points:BL (baseline, before start of epidural or anaesthesia),T-
0 (at arrival in the ICU), T-4 (four hours after arrival in the ICU), T-8 (eight
hours in ICU), and T-18 (eighteen hours in ICU). Blood samples for CRP and
white blood cell count were taken on day 1, 2, 4, and 6 after surgery. Arterial
plasma epinephrine and norepinephrine concentrations were analysed with
high-performance liquid chromatography with colorimetric electrochemical
detection [7].Plasma levels of BPI, IL-6 and LBP were measured using sandwich
enzyme linked immunosorbent assays (Elisa’s) as described previously [8]. CRP
concentrations were measured using a turbidimetric method; the white blood
cell count and the percentage of lymphocytes were measured with an auto-
mated white blood cell differential count according to the standard practice of
our hospital laboratory.
Statistical Analysis
The SPSS (SPSS Inc.,Chicago, IL) software for Windows,version 11.5 was used
for statistical analysis. Differences between groups were analysed using the
unpaired Student’s t-test for patient characteristics, and the non-parametric
Mann-Whitney U-test for all other data. Within group differences were
analysed with the non-parametric Wilcoxon Matched-Pairs Signed-Ranks test
followed by Bonferroni correction to allow for multiple comparisons as appro-
priate. Incidence of variables (the number of blood transfusions and of
piritramide doses) were analysed using the chi-square test. A P-value of < 0.05
was considered statistically significant. Results are presented as mean (SD) or
median (interquartile range).
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Results
All 30 patients completed the study, had stable haemodynamic values without
inotropic support throughout the study period, and had no postoperative
complications necessitating prolonged hospitalization (data not shown). The
epidural bolus dose resulted in sensory blockade from thoracic level 2 to 10 in
all patients of the TEA group. Patient and perioperative data were similar in
both groups (Table 1).
Plasma concentrations of epinephrine were about 80% less in the TEA group
compared to the REMI group during the first 4 postoperative hours (P < 0.05
at T-0 and T-4, Fig. 1). Plasma concentrations of norepinephrine did not change
and were similar in both groups (Fig. 1)
IL-6 remained unchanged in the REMI group, in contrast, epidural analgesia
was associated with an approximately five-fold increase from baseline of this
cytokine (P < 0.01, Fig. 2). As a result plasma concentrations of IL-6 were
different between both study groups (P < 0.05 at T-0, T-4 and T-8, Fig. 2)
during the first eight postoperative hours. Neutrophil activation, as indicated by
the BPI response, peaked at arrival in the ICU (200 – 300% increase from base-
line,P < 0.01) and was the same in both groups (P > 0.1 between both groups at
all time points, Fig. 2). The increase in plasma concentrations of LBP and CRP,
later markers of the inflammatory response, was also not different between both
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Table 1 Patient characteristics and perioperative data of the two patient groups.
REMI group TEA group
Age (yrs) 57 (11) 61 (10)
Height (cm) 172 (8) 171 (9)
Weight (kg) 76 (13) 78 (10)
Male : Female 13: 2 12: 3
Aortic Cross clamp time (min) 57 (25) 46 (17)
Cardiopulmonary bypass duration (min) 80 (31) 74 (23)
Coronary grafts (number) 4 (1) 4 (1)
Packed Cells:
Number of patients transfused 7 10
Number of packed cells transfused 24 26
Number of patients needing escape analgesia 7 0 *
Ventilator dependency time (min from stop sedation) 315 (169) 153 (101) *
REMI group = remifentanil group. TEA = thoracic epidural group. Data are presented as mean
(SD). Statistical significance: * P< 0.001
groups (P > 0.1 at all time points, Fig. 2 and 3). White blood cell count and the
relative fraction of lymphocytes, as indicators of the cellular immune response
was also not different between both groups (Fig. 3).Epidural analgesia decreased
pain and ventilator dependency more effectively than opioid analgesia (Table 1).
Discussion
The present data show that the choice of anaesthetic technique affects the
inflammatory response to CABG surgery in addition to the well-known effect
of anaesthesia on the neuro-humoral limb of the homeostatic stress response.We
found that epidural analgesia had superior sympatholytic effects compared to
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Figure 1. Time course of plasma catecholamines in the thoracic epidural group () and in the
remifentanil group () during the first 18 hours after coronary artery bypass surgery.Dots and error
lines indicate median and corresponding interquartile range of plasma concentrations of
epinephrine and norepinephrine.* = P < 0.05 vs.corresponding baseline value (BL),# = P < 0.05
thoracic epidural group vs. remifentanil group.T-0,T-4,T-8,T-18 = 0,4,8,18 hours after arrival in
the intensive care unit.Plasmaepinephrine was significantly less in the epidural group during the first
four postoperative hours.
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Figure 2. Time course of inflammatory mediators in the thoracic epidural group () and in the
remifentanil group () during the first 18 hours after coronary artery bypass surgery.Dots and error
lines indicate median and corresponding interquartile range of plasma concentrations of Bacteri-
cidal Permeability Increasing Protein, Interleukin-6,and Lipopolysaccharide Binding Protein.* =
P < 0.05 vs.corresponding baseline value (BL),# = P < 0.05 thoracic epidural group vs.remifentanil
group.T-0,T-4,T-8,T-18 = 0,4,8,18 hours after arrival in the intensive care unit.Interleukin-6 was
significantly less in the remifentanil group during the first eight postoperative hours.
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Figure 3.Time course of C-reactive Protein,number of leukocytes,and number fraction of Lymp-
hocytes in the thoracic epidural group () and in the remifentanil group () during the first 6 days
after coronary artery bypass surgery.Dots and error lines indicate median values and corresponding
interquartile range. * = P < 0.05 vs. corresponding baseline value (BL), # = P < 0.05 thoracic
epidural group vs.remifentanil group.PO1,POD2,POD4,POD6 = 1,2,4,and 6 days after surgery.
No significant differences between groups of these immunological parameters were measured.
opioid analgesia as indicated by decreased plasma epinephrine concentrations in
the TEA group. These data confirm the findings of previous studies [9,10], and
can be explained from a decreased neural afferent input from the site of injury
from epidural analgesia. In contrast, even large doses of opioids cannot
completely prevent increases in plasma catecholamines during cardiac surgery
[11,12], and it has been shown that the sympatholytic effect of the new opioid
remifentanil is similar to that of the more traditional opioids [13]. The finding
that epidural analgesia did not affect plasma norepinephrine concentrations is
not in contradiction with its sympatholytic effect because it has been shown that
high thoracic epidural analgesia decreases cardiac norepinephrine spill over from
sternotomy without affecting plasma norepinephrine concentrations [14]. The
relatively short duration of difference in sympatholytic effect may be explained
by a decrease in the amount of the neural blockade associated with the use of a
relatively small dose of local anaesthetics.
An important finding in this study is that the anaesthetic technique modu-
lates the proinflammatory cytokine response after on-pump CABG.This can be
concluded from the increased plasma concentration of IL-6 in the EPI group
compared to the REMI group during the first eight hours after surgery. It is
likely that intra-operative factors caused this difference because this cytokine is
known to be produced 2 to 4 hours after tissue damage.Of these intra-operative
factors, the anaesthetic technique most likely caused this difference because
most other factors controlling the IL-6 response; surgical procedure, duration of
bypass, and the amount of blood transfused [15], were similar in both groups. In
accordance with our findings, there is growing evidence that anaesthetic tech-
niques, and epidural anaesthesia in particular,modulate immunity of the surgical
patient [16]. However, epidural analgesia, in general, does not affect the inflam-
matory IL-6 response to surgery. A possible explanation for the increased IL-6
response in our EPI group may be related to the improved sympatholysis in this
group, because sympathetic activation is known to inhibit the production of
proinflammatory cytokines [17]. However, in a previous study in CABG
patients, differences in sympathetic tone were not translated into differences in
IL-6 release [18]. Alternatively, a direct suppressive effect of remifentanil on the
inflammatory cascade may explain the difference in IL-6. The IL-6 plasma
concentrations of 100 pg mL-1 measured in our REMI group are similar to
those measured previously after remifentanil anaesthesia [19]. These values are
less than one fourth of those measured in presence of either epidural-based or
long-acting opioid-based cardiac anaesthetic techniques [18,20]. There is
growing evidence that opioids have a suppressive effect on cells of the immune
system, either indirectly from their central nervous system mediated hormonal
effects or from direct interactions with the μ3 opioid receptors on cells of the
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immune system [2].Theoretically,opioids should affect also the IL-6 response to
surgery because monocytes, which secrete IL-6, have opioid receptors [21].
However, the evidence for this theory is equivocal. Crozier and colleagues [22]
showed that the opioid alfentanil diminished the IL-6 response compared to
inhalational anaesthesia,whereas Taylor and colleagues [23] showed no effect of
fentanyl on IL-6 release. These contrasting results may be explained because
there is evidence that opioids have differentiated immunological effects [24]. In
accordance with a suppressive effect of remifentanil on inflammatory responses,
it has been shown that this opioid suppresses natural killer function [25] and
inhibits the early local inflammatory response in rats [26]. However, to date
there are no studies which measure its effect on IL-6 release.
The clinical implications of this difference in IL-6 response remain uncertain,
as the immune system is complex and difficult to assess from individual tests. It is
important to stress that, in the current study, this effect of anaesthetic technique
on IL-6 was not accompanied by differences in LBP, CRP, and number of
leukocytes and leukocytes subsets, which are later markers of the immune
response. An intriguing first implication of our finding could be a decreased
likelihood for adverse outcome after remifentanil anaesthesia, because there are
reports linking increased IL-6 levels with adverse outcome [27]. However, anal-
gesia was superior, and ventilator dependency was shorter in the TEA group.
Also, the association between IL-6 and adverse outcome seems to be only valid
in the presence of an overwhelming systemic release of this cytokine, such as in
sepsis. A second implication of the decreased IL-6 response during remifentanil
anaesthesia is a potential increased risk at infectious complications. This is
because IL-6 is necessary for initiating an effective inflammatory response
against infection. In the current study there were no infectious complications in
neither group but our study was underpowered to investigate such an effect.
A limitation of the current investigation is that the study period of approxi-
mately 24 hours was rather short, because neuro-endocriene and inflammatory
changes after cardiac surgery are known to last about three days. However the
peak change of most measured variables in the current study had already
occurred within the study period.Another limitation is that this study could not
be blinded, which could have influenced the results on detubation time and on
pain measurement. However, the moment of detubation and administration of
analgesics were strictly protocolized and performed by nurses not involved in
the study.
In conclusion, this is the first study in which the effects of two different fast
track anaesthetic techniques on both sympathetic and inflammatory responses
during the early postoperative period after coronary artery surgery were evalu-
ated.We showed that the epidural-based anaesthetic technique resulted in supe-
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rior sympatholysis and that the remifentanil-based technique was associated
with a decreased proinflammatory cytokine response. Therefore, this study adds
to the growing evidence that anaesthetic techniques affect immunological
homeostatic responses in addition to their well-known effect on neurohumoral
responses.
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CHAPTER 4
Dexmedetomidine decreases perioperative
myocardial lactate release in dogs
Henriëtte M. Willigers, Frits W. Prinzen, Paul M. Roekaerts, Simon de Lange
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Abstract
The sympatholytic effect of the α2-adrenergic agonist dexmedetomidine may
decrease emergence-related myocardial ischemic load in patients. However, a
direct measure of myocardial ischemia such as myocardial lactate release is diffi-
cult to obtain in patients. Therefore, we studied mongrel dogs and measured
myocardial lactate release, myocardial oxygen supply, hemodynamic parameters,
and neurohumoral indices of the stress response. After induction of a standard-
ized degree of borderline myocardial ischemia, either dexmedetomidine
(Dexmed group, n = 9) or normal saline (Control group, n = 9) was infused.
Measurements were repeated at the end of the anesthetic period, and every 10
minutes during the 90-minutes emergence period. In the Dexmed group
cumulative emergence-related lactate release was 46% lower than in the Control
group (95% CI = 20 to 80%, P = 0.02). Simultaneously, dexmedetomidine
increased the endo-/epicardial blood flow ratio by 35% (Control group: 0.4 ±
0.1, Dexmed group: 0.6 ± 0.1 endo/epi ratio, P = 0.03). These anti-ischemic
effects of dexmedetomidine were accompanied by lower plasma concentrations
of norepinephrine (126 vs. 577 pg/ml) and epinephrine (158 vs.1909 pg/ml),
and a lower heart rate (123 ± 6 vs.160 ± 10 beats/min, Dexmed vs. Control).
The anti-ischemic effect of dexmedetomidine started prior to emergence as
evidenced by a lower prevalence of myocardial lactate release at that time
(Dexmed: 0/8, Control 4/7 dogs lactate release prior to emergence, P = 0.03).
Implications: Dexmedetomine decreases plasma catecholamines and heart rate
during emergence from anesthesia. In dogs with a coronary stenosis these
sympatholytic effects decrease myocardial lactate release, and therefore mini-
mize emergence-related myocardial ischemia.
Key Words: myocardial ischemia, postoperative complications, α2-adrenergic
agonists, sympatholysis.
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Introduction
Early postoperative myocardial ischemia is one of the most important risk
factors for adverse cardiac outcome in surgical patients with coronary artery
disease1. Because this risk factor appears related to the stress response associated
with surgery and emergence from anesthesia, methods to reduce this stress
response have been studied. Examples include epidural analgesia, profound
opioid analgesia, and administration of β-adrenoceptor antagonists or α2-
adrenergic agonists2.The last modality in particular seems promising because, in
contrast to β-adrenoceptor antagonists, 2-agonists reduce overall tonic sympa-
thetic action, reduce anesthetic requirements, and induce analgesia and
anxiolysis3.
It is well known that α2-adrenergic agonists can attenuate the stress response
associated with emergence from anesthesia4-6. However, whether this translates
to less postoperative myocardial ischemia is unknown. This is partly because
until now only 2 studies have focused directly on this issue7, 8. And, although
these studies show that α2-agonists decrease the incidence of emergence-related
ST-depression and postoperative cardiac deaths in high-risk surgical patients, no
effect on myocardial infarction has been demonstrated.
One of the main reasons for the paucity of information on the effect of α2-
agonists on postoperative myocardial ischemia, is the difficulty to select a prac-
tical and clinical relevant outcome measure. The outcome measure myocardial
infarction has a low incidence, necessitating studying a large number of patients.
Selecting ST-segment changes as an outcome measure may not always be clini-
cally relevant because they also result from changes in temperature, serum elec-
trolytes, position, and from administration of drugs9. A more precise measure of
myocardial ischemia, but difficult to obtain in patients, is the presence of lactate
release from the myocardial area at risk.Also, it has been shown that not the inci-
dence but the load (i.e. duration) of myocardial ischemia is most significantly
associated with adverse cardiac outcome10, and therefore may be a more
appropiate outcome measure.
Therefore, our aim was to determine in a placebo-controlled study if
dexmedetomidine, the most specific 2-agonist available, can decrease cumula-
tive myocardial lactate release in dogs having a coronary stenosis and emerging
from surgery and anesthesia.To obtain more insight in potential mechanisms we
also measured the effects of dexmedetomidine on hemodynamic parameters,
neurohumoral indices of the stress response, and on indices of myocardial
oxygen supply and demand.
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Methods
Animal preparation
With the approval of the Animal Care and Use Committee at the University of
Maastricht we studied 18 adult mongrel dogs.After induction of anesthesia with
20 mg/kg sodium thiopental intravenously, the dogs were intubated and venti-
lated with halothane in oxygen / nitrous oxide. After thoracotomy, a screw-
driven plastic occluder was placed non-constrictively distal to the first diagonal
branch of the left anterior descending coronary artery (LAD). This occluder
allows producing a fixed stenosis from controllable narrowing of coronary
arteries. Catheters were inserted into the left femoral artery, the left anterior
coronary vein, and a distal pulmonary artery for arterial (A), coronary venous
(CV), and mixed venous (MV) blood sampling. To measure regional myocardial
blood flow, a catheter for injection of microspheres was implanted in the left
atrial appendage. Pressure sensors (Sentron 180 S, Cordis, Roden, the Nether-
lands) were inserted through the right femoral artery into the ascending aorta
and left ventricle (LV). Ultrasonic transit-time flow probes (Transonic Systems,
Ithaca, NY) were placed around the aortic root and just proximal to the coro-
nary occluder.Heart rate was monitored using limb lead II of the electrocardio-
gram. To measure regional myocardial shortening, a pair of 1.5 mm-diameter
piezoelectric crystals was inserted parallel to circumferential midwall fibers in
the area perfused by the LAD and connected to a digital sonomicrometer
(Sonometrics Corporation, London, Ontario, Canada)
Throughout the experiment, all signals were continuously displayed on
monitors, and the corresponding values were stored every minute. During each
period of measurement, digitized signals (12 bit A/D interface, sample
frequency 200 Hz) and corresponding beat-to-beat values were stored for 5
minutes. During off-line processing, all data of a 2-minute stable period (i.e. less
than 5% heart rate variation) within this 5-minute acquisition period were aver-
aged.
All blood samples were collected on ice. Those to be analyzed afterwards
were centrifuged within 15 min at 4C to separate plasma,and stored at -70C.
Study protocol (Fig. 1)
At the start of the study protocol anesthesia was standardized to 1% halothane in
oxygen / nitrous oxide (33% / 66%).After 20 minutes a stenosis of the LAD was
applied, standardized as the tightest stenosis not resulting in myocardial lactate
release during stable anesthesia.We aimed to increase the probability of myocar-
dial lactate release from emergence-related stress responses by creating compa-
rable degrees of borderline ischemia, and used lactate release as primary
outcome variable.
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To create similar borderline ischemia in both groups, the coronary artery was
narrowed step by step at 5-minutes intervals until the poststenotic myocardium
released lactate, i.e. [(CV-A) lactate] > 0. Then the occluder was released step by
step until lactate release just ceased. During this procedure, lactate concentra-
tions were measured within 3 minutes using an absorption photometric method
(DR Lange cuvette test LKM 140,Berlin,Germany).After a stabilization period
of 15 minutes the following baseline variables were measured: 1) hemodynamic
variables (heart rate, aortic pressure, end-diastolic and maximum first derivative
of LV pressure (dPdTmax), and aortic flow); 2) stress hormones (arterial plasma
concentrations of norepinephrine, epinephrine, and cortisol); 3) indicators of
myocardial oxygen balance (LAD flow, regional myocardial blood flow, frac-
tional oxygen extraction, and poststenotic myocardial lactate release).
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Figure 1. Schematic representation of the study protocol. Black arrows represent periods of
measurements of hemodynamic variables; hemoglobin content; arterial and coronary venous
blood gases; poststenotic coronary flow, lactate release, and regional myocardial contractile func-
tion. Stress hormones (SH) and regional myocardial blood flow (MBF) were measured less
frequently. Time axis shows excact number of minutes from start sponteneous breathing (first
emergence period measurement),and approximate number of minutes before this event. Note
that baseline stenosis measurements were performed BEFORE study drug administration.
P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia. R = first emergence
period measurement at start of spontaneous Respiration. 2,3,4, . . . = emergence period measure-
ments
After these baseline stenosis measurements the study-drug was administered.
Animals were randomly assigned to one of 2 groups: those receiving
dexmedetomidine (loading dose 0.5 μg kg-1 followed by a continuous infusion
of 0.6 μg.kg-1.hour-1, Dexmed group, n = 9), or those receiving placebo (0.9%
NaCl, Control Group, n = 9). We did not blind administration of the study-
drug because the marked bradycardic effect of dexmedetomidine makes this
virtually impossible. The target plasma concentration of dexmedetomidine was
0.5 ng ml-1 because this concentration does not have major vasoconstrictive
effects (11), and reduces sympathetic tone effectively in dogs(12) and in humans
(4). The corresponding infusion scheme (timing and dose) was obtained from
pharmacokinetic data of our pilot study.
About 10 minutes after starting the study-drug, the chest wall was closed and
care was taken to maintain the position of the occluder by observing coronary
flow and myocardial shortening signals. The pneumothorax was evacuated by
careful manual inflation of the lungs. To mimic perioperative blood loss and to
decrease the number of animals needed in our study, blood was collected from
the femoral artery and replaced simultaneously with a colloid solution
(Haemacel®, Behringwerke AG, Marburg) until a hemoglobin value of approxi-
mately 6.5 mmol L-1 was reached. After completion of surgery, 0.01 mg kg-1
buprenorphine was injected intramuscularly for postoperative analgesia (13), the
dogs were restrained, and measurements were repeated. Then the emergence
period was started by changing the inspiratory gas to 100% oxygen. The first
emergence period measurement was made at the moment the dogs first
breathed spontaneously. This was done to standardize the level of consciousness
during the emergence period. Then, measurements were repeated every 10
minutes during 90 minutes. By protocol no interventions were made if ventric-
ular fibrillation (VF) occurred. At the end of the experiment, the dogs were
euthanized by pentobarbital overdose, and their hearts were stored at –20C for
regional blood flow analysis.
Measurements and calculations
Myocardial ischemic load: Plasma lactate concentrations were determined
spectrophotometrically (Cobas Bio System, Hoffman La Roche, Basel, Switzer-
land) afterwards, and the presence of myocardial lactate release ([(CV – A)
lactate] > 0) was identified. Of each dog the cumulative myocardial ischemic
load of the emergence period, our primary outcome measure, was calculated as
the percentage of measurements indicating myocardial lactate release. In dogs
that died from VF, missing lactate measurements were added to the myocardial
ischemic load provided that VF occurred during a period of lactate release. We
consider this appropriate because VF is a more severe consequence of myocar-
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dial ischemia than is myocardial lactate release, and not coding these measure-
ments would have underestimated myocardial ischemia in these dogs.
Myocardial oxygen extraction and consumption: Hemoglobin content (Hb
(mmol/L)) and oxygen saturation (SaO2 (%)) of A, CV, and MV samples were
measured with a hemoxymeter (OSM-2, Radiometer, Copenhagen,Denmark),
and oxygen tension (PO2 (kPa)) was measured with a blood gas analyzer (Radi-
ometer ABL 3). The O2 content (CaO2 (mmol/L)) was calculated as: Hb 
SaO2 + 0.0102  PO2. From this, oxygen extraction and consumption were
calculated using standard formulas.
Regional myocardial shortening: Myocardial circumferential segment lengths
at begin ejection (Be sl) and end ejection (Ee sl) were measured using the aortic
flow signal to delineate the ejection period. From these, percentage systolic
shortening during the ejection period (Sse) was calculated as SSe (%) = 100 ×
(Be sl – Ee sl)/ Be sl.
Regional myocardial blood flow: Regional myocardial blood flow was
measured with fluorescent labeled microspheres (polystyrene, diameter: 15.5
μm  2%, Molecular Probes, Eugene, OR) of 6 different colors (blue-green,
yellow-green, orange, red, crimson, and scarlet) as described in detail elsewhere
(14). Briefly, for each measurement approximately 4 × 106 microspheres of a
single color were injected into the left atrium; simultaneously a reference arterial
blood sample was withdrawn. Afterwards, several adjacent myocardial samples
were taken from the poststenotic myocardial wall and from the remote non-
ischemic myocardial wall, and divided into subendo- and subepicardial samples.
Microspheres were isolated, their fluorescence determined, and regional
myocardial flow was calculated. Of the poststenotic myocardial wall, the area
with lowest flow immediately after aplication of the stenosis was used for anal-
ysis.
Plasma concentrations of stress hormones and dexmedetomidine: Catechol-
amines were measured fluorimetrically (15). Serum cortisol concentration was
determined using solid-phase, chemiluminescent enzyme immunoassay
(Immulite®, Cortisol kit, DPC, Los Angeles). Plasma concentrations of
dexmedetomidine were determined by gas chromatography-mass spectrometry
(16) at Farmos Research, Turku, Finland.
Pressure work index: The pressure work index (PWI, equivalent to
μmol.min-1.g-1) was calculated as a measure of myocardial oxygen demand (17)
PWI = C1 (SBP × HR) + C2 (0.8 SBP + 0.2 DBP) × HR × SV/BW + 0.57
Where
SV = stroke volume (ml)
SBP = systolic blood pressure (mmHg)
DBP = diastolic blood pressure (mmHg)
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BW = body weight (kg)
C1 = 1.63 × 10–4
C2 = 1.30 × 10–4
Statistical analysis
From the 18 dogs, 1 dog from each group was not included in the statistical
analysis; in the control group because of VF before administration of the study-
drug, in the dexmed group because of severe postoperative hemorrhage. Of
some variables data from at most 1 experiment were missing due to technical
problems. Data are presented as mean  SEM, unless stated otherwise.
Emergence period values of each experiment were summarized as median
values. This was done because the use of a summary measure is considered the
most appropriate approach to analyze serial measurements (18). Differences
between groups were evaluated by Mann-Whitney U test, within group
changes by Wilcoxon Signed Rank Test with Bonferroni correction, and differ-
ences between ratios by Fisher’s Exact Test. A P-value < 0.05 was considered
statistically significant. Additionally, individual timepoints were analyzed using
Two Way Repeated Measures Anova followed by Tukey test for multiple
comparisons.
Results
Effects of dexmedetomidine during the emergence period.
The cumulative myocardial ischemic load was 46% lower in the Dexmed group
than in the Control group (95% CI = 20 to 80%, P = 0.02, Fig. 2). Simulta-
neously, dexmedetomidine increased total coronary blood flow distal to the
stenosis (figure 3), especially in the endocardial layers, as indicated by a 35%
higher endo- / epicardial blood flow ratio (Table 1). The other determinants of
myocardial oxygen supply, hemoglobin concentration and partial arterial
oxygen pressure, were similar in both groups (Table 1). Regarding demand,
dexmedetomidine decreased heart rate during the emergence period by
approximately 23%, but it did not affect aortic flow, aortic pressure and PWI
(Table 2). In neither group myocardial ischemia was preceded by a change in
heart rate, blood pressure, or coronary flow (data not shown).The differences in
incidence (%) between both groups of (1) myocardial lactate release (95% CI = -
19% to 65%); and (2) VF (95% CI = -5 to +62%) were not statistically signifi-
cant (Fig. 2B).
With regard to the emergence-related stress response, plasma catecholamines,
heart rate, and oxygen consumption of the body were lower in the Dexmed
group than in the Control group (Table 2, Fig. 3). Of these, dexmedetomidine
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Figure 2.Effect of dexmedetomidine on poststenotic myocardial lactate release in dogs emerging
from anesthesia.Panel A: Time course of individual coronary venous (CV) to arterial (A) lactate
differences in the Control group (left panel) and Dexmed group (right panel). In 1 dog of the
Control group no lactate data were obtained because of technical problems. Panel B: Data from
panel A represented as either presence () or absence () of episodes myocardial lactate release.
Panel C: Mean values ± SEM of the cumulative myocardial ischemic load during the emergence
period (= (episodes lactate release or VF / total emergence period measurements) X 100%). P =
before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia. R = first emergence period
measurement at start of spontaneous Respiration.2,3,4, . . .= emergence period measurements.#:
P < 0.02: Dexmed vs. Control group.
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Figure 3. Changes in time in hemodynamics, plasma norepinephrine concentration, and
poststenotic myocardial oxygenation in the Dexmed group () and Control group (). Values
are plotted as mean percentages of baseline stenosis measurements. Error bars indicate SEM. For
plasma norepinephrine concentrations median values are plotted. Arrow indicates start adminis-
tration of study drug.P = before coronary stenosis. St = coronary Stenosis. S = Stop anesthesia.R
= first emergence period measurement at start of spontaneous Respiration.2,3,4, . . .= emergence
period measurements.
Absolute values of these data are given in table 1and 2. * P < 0.05, Control group vs. Dexmed
group (Two Way Repeated Measures Anova on absolute values followed by Tukey test for
multiple comparisons).
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Table 1. Changes in Indices of Myocardial Oxygen Supply
Variable Area Group Pre-stenosis
(Pre- drug)
Stenosis
(Pre- drug)
Stop
(Drug)
Emergence
(Drug)
Endocardial flow Stenotic Control 1.0 ± 0.1 0.3 ± 0.1* 0.3 ± 0.1 0.4 ± 0.1
ml.min-1.g-1 Dexmed 0.8 ± 0.1# 0.3 ± 0.1* 0.5 ± 0.1 0.6 ± 0.1
Epicardial flow Stenotic Control 1.2 ± 0.1 0.8 ± 0.1* 0.8 ± 0.1 1.0 ± 0.1
ml.min-1.g-1 Dexmed 0.9 ± 0.1 0.9 ± 0.2 0.7 ± 0.1 1.0 ± 0.1
Endo-/epicardial Stenotic Control 1.0 ± 0.1 0.5 ± 0.1* 0.4 ± 0.1 0.4 ± 0.1
blood flow ratio Dexmed 0.8 ± 0.1 0.4 ± 0.1* 0.7 ± 0.1*# 0.6 ± 0.1#
Endocardial flow Remote Control 1.2 ± 0.1 1.1 ± 0.2 1.1 ± 0.1 1.4 ± 0.2
ml.min-1.g-1 Dexmed 0.9 ± 0.1 1.2 ± 0.2 0.9 ± 0.1 1.3 ± 0.1
Epicardial flow Remote Control 1.1 ± 0.1 1.0 ± 0.2 1.0 ± 0.1 1.4 ± 0.1*
ml.min-1.g-1 Dexmed 0.9 ± 0.1 1.2 ± 0.2 0.8 ± 0.1 1.2 ± 0.1
Endo-/epicardial Remote Control 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1 1.1 ± 0.1
bloodflow ratio Dexmed 1.0 ± 0.1 1.0 ± 0.1 1.1 ± 0.0 1.0 ± 0.0
Fractional O2 Stenotic Control 0.55 ± 0.03 0.73 ± 0.01
* 0.77 ± 0.02 0.79 ± 0.03
extraction Dexmed 0.60 ± 0.04 0.75 ± 0.04* 0.70 ± 0.05 0.76 ± 0.04*
LAD flow Stenotic Control 33 ± 4 16 ± 2* 14 ± 3 14 ± 3
ml/min(flow probe) Dexmed 27 ± 4 12 ± 2* 14 ± 2 20 ± 4 *
Hemoglobin (A) Control 8.5  0.3 9.0 ± 0.3 6.2 ± 0.3* 6.5 ± 0.6
mmol/L Dexmed 8.2  0.3 7.7 ± 0.6 6.7 ± 0.5 6.9 ± 0.4
pO2(A) Control 13  1 12  1 18  1
* 16  2
kPa Dexmed 16  2 16  1 18  2 11 ± 2*
Data are mean  SEM. Pre-stenosis and Stenosis values are measured just before, and just after
application of the coronary stenosis. Stop values are measured just prior to stopping the anes-
thetics, Emergence values are median values of all time points during emergence. Pre- drug =
before starting study drug (dexmedetomidine or NaCl). Drug = in presence of study drug. LAD
= left anterior descending coronary artery. A = Arterial, * = P < 0.05 compared to preceding
measurement in the same group, # = P < 0.05, Control group vs. Dexmed group.
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Table 2. Changes in Hemodynamic Variables and Stress Hormones.
Variable Group Pre-stenosis
(Pre- Drug)
Stenosis
(Pre- Drug)
Stop
(Drug)
Emergence
(Drug)
Heart Rate Control 139  4 145  6 148  9 160  10*
beats/minute Dexmed 125  4 # 131  5 104  3* # 123  6* #
Systolic Aortic Pres Control 109  4 109  5 100  5 113  8
sure mmHg Dexmed 99  5 97  4 90  5 113  5
dPdTmax Control 1365  97 1368  90 1384  123 2153  185
*
mmHg/sec Dexmed 1323  79 1270  76 1012  42*# 1781  152*
Enddiastolic LVP Control 11  2 12 ± 1 10 ± 1 5 ± 1
mmHg Dexmed 8  1 8 ± 1 # 9 ± 1 4 ± 1*
Aortic Flow Control 3.5  0.3 2.8 ± 0.3 2.4 ± 0.2 2.8 ± 0.3
L/min Dexmed 2.8  0.2 2.4 ± 0.1 1.9 ± 0.1*# 2.5 ± 0.1*
Pressure Work Index Control 4.7  0.2 4.5 ± 0.3 4.0 ± 0.2 5.1 ± 0.5
μmol.min-1.g-1 Dexmed 3.8  0.2 3.7 ± 0.2 2.9 ± 0.1*# 4.2 ± 0.3*
SSE Control 5  1 6 ± 1 4 ± 1 5 ± 1
% Dexmed 7  1 6 ± 1 3 ± 1* 7 ± 1*
O2 consumption body Control 0.22 ± 0.02 0.24 ± 0.02 0.22 ± 0.02 0.31 ± 0.02
mmol.kg-1.min-1 Dexmed 0.21  0.01 0.19 ± 0.02 0.19 ± 0.01 0.22 ± 0.02#
Cortisol Control 438 ± 40 405 ± 46 389 ± 52
nmol/L Dexmed 439 ± 53 400 ± 80 402 ± 81
Norepinephrine Control 116 (115 - 211) 180 (175 - 348) 577 (305-609)*
pg/ml Dexmed 114 (54 - 178) 61 (27 - 173)# 126 (51-286)#
Epinephrine Control 435 (320 - 799) 395 (238 - 475) 1909 (136-3489)*
pg/ml Dexmed 281 (179 - 363) 84 (45 - 404) 158 (91-1448)#
Data are mean  SEM, except plasma catecholamines which are presented as median (25 – 75%
interval). Pre-stenosis and Stenosis values are measured just before, and just after application of the
coronary stenosis. Stop values are measured just prior to stopping the anesthetics, Emergence values
are median values of all time points during emergence. Pre-drug = before starting study drug
(dexmedetomidine or placebo). SSE = systolic shortening of the ejection period. * = P < 0.05
compared to preceding measurement in the same group, # = P < 0.05, Control group vs. Dexmed
group.
prevented only an increase in plasma catecholamines compared to the preceding
intraoperative measurements. The time to regain spontaneous breathing after
stopping the anesthetics, as a measure of emergence, tended to be longer in the
Dexmed group, but this was not statistically significant (Dexmed group: 30 ± 6,
Control Group: 16 ± 2 min; 95% CI for the difference between groups = -3 to
+29 min, P > 0.2).
Effects of dexmedetomidine prior to emergence.
Prior to emergence the prevalence of myocardial lactate release was 57% lower
in the Dexmed group than in the Control group (95% CI = 20% to 94%, P=
0.03, Stop values Fig. 2B). Simultaneously, dexmedetomidine decreased plasma
concentrations of norepinephrine by 66%, decreased myocardial oxygen
demand (PWI) by 29% (Table 2) and increased the endo-/epicardial blood flow
ratio by 45% (Table 1).
Experimental model
Intra-operative procedures were the same in both groups. First, application of
the stenosis resulted in a similar decrease in myocardial oxygenation. This is
because:1) myocardial lactate release was abcent in both groups (Control Group:
-0.1 ± 0.1;Dexmed group -0.2 ± 0.0 mmol/ L (CV – A) [lactate],P = 0.16,Fig.
2A stenosis values), 2) endocardial flow decreased similarly (Dexmed group: 59
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Figure 4. Stability of plasma concentrations of dexmedetomidine (mean ± SEM, n = 8 dogs) in
relation to target plasma concentration of 0.5 ng/ml. P = before coronary stenosis. St = coronary
Stenosis. S = Stop anesthesia (about 35 minutes after starting dexmedetomidine). R = first emer-
gence period measurement at start of spontaneous Respiration. 2,3,4, . . . = emergence period
measurements
± 6 %, Control group: 66 ± 8 % decrease; P > 0.5, Table 1), and 3) baseline
stenosis values were similar for all variables except EDP (stenosis values Table 1,
2, Fig. 2A). Second, the duration of surgery and anesthesia was the same in both
groups because the time between ‘stenosis’ and ‘stop anesthesia’ measurements
was 81 ± 8 minutes in the Dexmed group, and 76 ± 9 minutes in the Control
Group (95% CI = -19 to + 20 minutes, P > 0.5). Finally, intra-operative
hemodilution resulted in a similar hemoglobin (Table 1)
Plasma concentrations of dexmedetomidine were stable and close to our
target of 0.5 ng/ml (Fig. 4), and no animal in either group required additional
buprenorphine.
Discussion
In the current study the α2-agonist dexmedetomidine decreased myocardial
ischemic load in dogs with a coronary stenosis and emerging from anesthesia.
This anti-ischemic effect of dexmedetomidine was associated with a decreased
sympathetic tone and improved myocardial oxygen balance.The unique feature
of our study was that we used invasive measurements of myocardial oxygenation
of the area of risk that are not obtainable from human studies.Our data therefore
may help explain clinical findings that perioperative infusion of an α2-agonist
has potential to limit postoperative myocardial ischemia7.
A decrease in myocardial ischemic load is a clinically relevant outcome
measure because it has been shown that several periods of myocardial ischemia
have a cumulative effect and can cause subendocardial necrosis in dogs19. In
accordance, in humans prolonged duration of ST-segment depression leads to
myocardial damage as measured by cardiac troponin-1 levels20 and is associated
with adverse cardiac outcome10. If dexmedetomidine can decrease the inci-
dence of myocardial ischemia during emergence remains unknown from the
current study because it was not powered for this outcome measure (e.g. to
detect differences in incidence of myocardial ischemia with power: 0.80 and α
= 0.05, 62 dogs in each group would have been necessary.) However, the
importance of decreasing the incidence of myocardial ischemia, in addition to
its load, remains unknown.
The decrease in emergence-related myocardial ischemic load from
dexmedetomidine may be explained from its sympatholytic effects, improving
the myocardial oxygen supply/demand ratio. In accordance with previous
studies in humans6 and in dogs21, dexmedetomidine had sympatholytic effects
during the emergence period, as indicated by a decrease in plasma catechol-
amines and heart rate. These effects coincided with a redistribution of supply to
the vulnerable endocardium as indicated by an increased endo-/ epicardial
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blood flow ratio. Although relatively large doses of α2-adrenergic agonists may
produce coronary vasoconstriction 11, the redistribution of blood flow toward
the endocardium indicates that the sympatholytic and heart rate-lowering
effects of dexmedetomidine most likely prevailed at the dose used. Coronary
artery thrombosis may also decrease myocardial blood flow, and thus supply.
However, this is an unlikely event in the current study, because dogs are not
prone to coronary atherosclerosis, and we did not observe any macroscopic
intracoronary thrombi at dissection afterwards.
Other determinants of myocardial oxygen supply, plasma hemoglobin values
and arterial oxygen tension, were not different between both groups, and there-
fore are not likely to confound the observed differences in myocardial lactate
release.Hemoglobin values were 6-7 mmol/L after hemodilution.These values
are generally accepted for almost all surgical patients22, and as such do not lead to
myocardial ischemia. However, if the vasodilating capacity of the coronary
artery is limited, moderate hemodilution may increase the risk of myocardial
ischemia23.This effect was considered ethically advantageous because it reduced
the number of animals required.
Of the hemodynamic factors potentially involved in the genesis of emer-
gence-related myocardial ischemia, dexmedetomidine decreased heart rate. A
low heart rate is of pivotal importance in reducing myocardial ischemia because
it improves supply from a prolonged diastolic perfusion time and is the most
important determinant of myocardial oxygen demand24.
Thus, the decrease in myocardial ischemic load from dexmedetomidine in
the current study most likely results from its sympatholytic effects, mitigating
emergence-related tachycardia and improving myocardial oxygen balance.
The beneficial effect of dexmedetomidine started intra-operatively because it
decreased the prevalence of myocardial ischemia prior to emergence. This coin-
cided with a decrease in demand, as indicated by the PWI, and with an
improved endo/epicardial blood flow ratio. The finding that dexmedetomidine
decreased myocardial oxygen requirements during the intra-operative period is
in accordance with our previous studies in halothane-anesthetized dogs11, 25. We
started the infusion of dexmedetomidine intra-operatively to obtain stable
plasma concentrations of dexmedetomidine at the start of the emergence
period. This approach also may have clinical relevance because it has been
shown recently in vascular surgery patients that most ischemic events occur
between 50 minutes before and 60 minutes after the end of surgery20.
A critical aspect of our study is the methodology to create a stable coronary
stenosis because small changes in diameter may cause large changes in coronary
flow.However, immediately after application of the stenosis the relative decrease
in poststenotic endocardial flow was the same in both groups. Also, major
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kinking of the plastic screw occluder is unlikely because no sudden decreases of
the coronary flow or myocardial shortening signals were observed.Most impor-
tantly, it is unlikely that potential variations in diameter of the stenosis explain
the differences in myocardial ischemic load between both groups because the
probability of these variations is the same in both groups.
In conclusion, a stable plasma concentration of dexmedetomidine of 0.5
ng/ml in dogs with a artificial coronary stenosis decreases the myocardial
ischemic load during the first 2 hours of emergence from halothane anesthesia.
This effect of dexmedetomidine can be explained by its sympatholytic and
heart rate-lowering effects improving myocardial oxygen balance. Although
extrapolation of our findings to the clinical setting should be performed with
care, our study suggests that perioperative infusion of α2 adrenergic-receptor
agonists may offer a pharmacologic means of decreasing the ischemic load on
the myocardium during emergence.
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Summary
Background and objective: The beta-adrenergic blocker esmolol and the
alpha2-adrenergic agonist dexmedetomidine have the potential to decrease
perioperative myocardial ischaemia.The pathophysiologic mechanisms involved
in these anti-ischaemic properties have not been thoroughly studied. We
compared the effects of esmolol and dexmedetomidine on two haemodynamic
indices of overall myocardial oxygen demand and on directly measured myocar-
dial oxygen consumption.
Methods: Eleven mongrel dogs were instrumented to measure aortic and left
ventricular pressure, aortic and left anterior coronary artery flow, and myocardial
wall thickening.
Variables related to myocardial oxygen metabolism were also determined.
Measurements were performed during four sequential experimental conditions
(control 1, esmolol, control 2, dexmedetomidine).
Results:Esmolol and dexmedetomidine decreased haemodynamic indices of
myocardial oxygen demand to a similar extent: esmolol decreased the rate-pres-
sure-product by 16 ± 3% and the pressure-work-index by 16 ± 3%,
dexmedetomidine decreased the rate-pressure-product by 26 ± 3% and the
pressure-work-index by 16 ± 7%. However, neither drug had an effect on
myocardial oxygen consumption, a direct measure of myocardial oxygen
demand.Sympatholytic doses of esmolol and of dexmedetomidine had different
haemodynamic effects. Dexmedetomidine had a more pronounced bradycardic
effect than esmolol (P = 0.01) and increased systolic aortic pressure by 15 ± 4%.
Esmolol decreased systolic aortic pressure by 8 ± 2%, and decreased indices of
myocardial contractility (dPdTmax and regional myocardial area decrease).
Conclusions: Esmolol and dexmedetomidine decreased haemodynamic
indices of myocardial oxygen demand to a similar extend but neither drug
decreased directly measured myocardial oxygen demand.
Keywords: Sympatholytics, Adrenergic Beta-Antagonists,Esmolol; Sympa-
tholytics, Adrenergic Alpha-Agonists, Dexmedetomidine; Heart, Coronary
Circulation, Drug Effects; Myocardium, Metabolism; Heart, Myocardial
Contraction
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Introduction
Perioperative sympatholysis from beta-adrenergic blockers and from alpha2-
adrenergic agonists has the potential to decrease the risk of postoperative
myocardial ischaemia and of cardiac death1. Therefore, the American Heart
Association guidelines recommend consideration of the use of either one of
these two classes of sympatholytic drugs in patients having or at risk for coro-
nary artery disease2.However, the pathophysiologic mechanisms involved in the
anti-ischaemic effects of these drugs have not been studied intensively. It is likely
that the postoperative increase in myocardial oxygen demand is an important
cause of myocardial ischaemia in patients having significant coronary artery
disease. This is because this category of patients has a reduced capacity to
increase coronary blood flow in response to an increase in myocardial oxygen
demand. Both the short-acting beta blocker esmolol and the most specific
alpha2 agonist dexmedetomidine have been shown to suppress postoperative
increases in blood pressure and heart rate, two important determinants of
myocardial oxygen demand3-6. Therefore it is likely that these drugs decrease
myocardial ischemia from a decrease in myocardial oxygen demand. However,
the effects of these drugs on myocardial oxygen demand are unknown,probably
because of the invasive nature of the measurements involved. Also, the
haemodynamic effects of an alpha2-agonist and a beta-blocker have not been
compared into detail.
The aim of this study was to determine and to compare the effects of the
beta1-blocker esmolol and the alpha2-agonist dexmedetomidine on myocardial
oxygen demand and on various haemodynamic indices of myocardial oxygen
demand. Because of the invasiveness of the measurement of myocardial oxygen
demand, these studies were performed in chloralose anaesthetized dogs.
Materials and methods
Animal preparation and instrumentation
Eleven adult mongrel dogs (31 ± 1.9 kg) were studied with the approval of the
Animal Care Committee of the University. Anaesthesia was induced with
sodium thiopental 25 mg kg-1 intravenously; the dogs were intubated and venti-
lated with oxygen 30% in nitrous oxide. Halothane (inspired concentration 1-
1.5%) was added to suppress somatic responses and to maintain haemodynamic
stability during thoracotomy and instrumentation. The chest was opened
through the left fifth intercostal space and the heart was suspended in a
pericardial cradle. The rectal temperature of the dogs was kept between 37° C
and 39° C by means of a thermostatically regulated heating mattress and a
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warmed operating room (24° C). Heart rate and rhythm were monitored using
ECG lead II.
Catheters were inserted into a femoral artery and the vein next to the left
anterior descending (LAD) coronary artery for arterial and coronary venous
blood sampling respectively.The coronary venous catheter was assumed to drain
the region of the myocardium supplied by the LAD artery. Pressure sensors
(Sentron 180 S, Cordis, Roden, the Netherlands) were inserted through the
right femoral artery into the ascending aorta and left ventricle. Ultrasonic
transit-time flow probes (Transonic Systems, Ithaca, NY) were placed around
the aortic root and around the LAD artery just proximal to the first diagonal
branch. A pulmonary artery catheter (Baxter) was introduced via the right
jugular vein into the pulmonary artery and connected to a thermodilution
cardiac output computer (Baxter Edwards SAT 2).The cardiac output measure-
ments,obtained by averaging triplicate thermodilution values,were compared at
regular intervals with the ultrasonic aortic flow measurements. Three inductive
coils were sutured to the left lateral epicardium in an equilateral triangle config-
uration to measure epicardial area decrease, an index of myocardial wall thick-
ening.
Study protocol
As soon as instrumentation was completed, nitrous oxide and halothane were
discontinued. A chloralose loading dose of 40 mg kg-1 was then administered,
followed by a maintenance infusion of 8 mg kg-1 h-1. The dogs were ventilated
with 40% oxygen in air to normocarbia.
After a stabilization period of at least 60 minutes, the following 4 successive
experimental conditions were studied in each dog:
1. Control 1
2. Esmolol: twenty minutes after starting esmolol HCl infusion (Ohmeda Inc.,
NJ, USA)
3. Control 2: twenty minutes after stopping the esmolol infusion
4. Dexmedetomidine: twenty minutes after starting dexmetomidine infusion
(Orion Corporation, Farmos Research, Turku, Finland) .
After the Control 1 measurements had been performed, the dose of isoprenaline
necessary to increase heart rate by more than 20% was determined as the
tachycardic dose in each dog.
After heart rate and other haemodynamic variables had returned to control 1
values,esmolol was given as a loading dose of 0.5 mg kg-1 min-1 for two minutes,
followed by a continuous infusion of 0.3 mg kg-1 min-1.To check that the beta1-
CHAPTER 5
72
adrenergic blockade from esmolol was adequate, the response to the tachycardic
dose of isoprenaline was tested before stopping the esmolol infusion.
Dexmedetomidine was given as a loading dose of 1 μg kg-1 over twenty
minutes, followed by a continuous infusion of 1.5 μg kg-1 hour-1 in NaCl 0.9%.
We aimed for a target plasma concentration of dexmedetomidine above 0.5 ng
ml-1, because this concentration reduces sympathetic tone effectively in
dogs7and in humans5. Because the pharmacokinetics of dexmedetomidine in
dogs were unknown at the time of the study, we used an infusion regimen
advised by Orion Corporation (Turku, Finland) and based on the
pharmacokinetic set in the STANPUMP software8.
During each experimental condition the following variables were measured:
1. haemodynamic indices: heart rate, systolic and diastolic aortic pressure, left
ventricular pressure, aortic flow and myocardial wall thickening.
2. variables related to myocardial oxygen metabolism: Arterial and LAD coro-
nary venous blood gas tensions, LAD coronary flow and, arterial haemo-
globin content.
To measure LAD flow relative to myocardial weight, the perfusion area of the
LAD was delineated by injecting methylene blue dye in the LAD at the end of
each experiment. Then the dogs were euthanized by a pentobarbital overdose,
and their hearts were excised. The methylene blue stained portion of the heart
was dissected off and weighed.
Data analysis
All haemodynamic and coronary flow signals were preamplified and then digi-
tized with a 16-channel, 12-bit A/D interface in a IBM-compatible PC.
Sampling frequency was 200 Hz for each channel. Signals were continuously
displayed on the computer screen, and during each experimental measurement
period beat to beat values were stored on the hard disk. For each measurement
period, the average of each variable was calculated over a stable haemodynamic
period of two minutes, i.e. less than 5% heart rate variation. Peak of first deriva-
tive of left ventricular pressure (LV dPdtmax) was derived from the left ventricular
pressure signal.
Systemic vascular resistance (SVR) was calculated as the quotient of mean
aortic pressure and mean aortic blood flow. Coronary vascular resistance (CVR)
was calculated as the quotient of mean aortic pressure and mean coronary blood
flow.
The following haemodynamic indices of myocardial oxygen demand were
measured:
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1. The pressure work index PWI9 = C1 (SAP  HR) + C2 (0.8 SAP + 0.2
DAP)  HR  SV/BW + 0.57, in μmol min-1 g-1
where
HR = heart rate in beats per minute
SV = stroke volume in ml
SAP = systolic aortic pressure in mmHg
DAP = diastolic aortic pressure in mmHg
BW = body weight in kg
C1 = 1.63  10-4
C2 = 1.30  10-4
2. The rate pressure product RPP = heart rate  systolic aortic pressure.
To study the effects of esmolol and dexmedetomidine on the relation between
haemodynamic indices of myocardial oxygen demand (MVO2) and measured
myocardial oxygen consumption, percentage changes in RPP and PWI were
plotted against percentage changes in measured MVO2.
To measure epicardial deformation, three inductive coils were sutured to the
left lateral epicardium. This method for measuring epicardial deformation and
its ability to detect changes in regional contractility has been validated in our
laboratory10,11. The coils were sutured in an equilateral triangle configuration to
measure area decrease, e.g. the reduction in area of the epicardial region
enclosed by the coils during the ejection period of the systole. Onset and end of
the ejection phase were determined from the cross over of the left ventricular
pressure and the ascending aortic pressure and from the dicrotic notch in the
aortic pressure signal, respectively. Because the volume of a certain part of the
ventricular wall does not change significantly throughout the cardiac cycle,
surface area decrease during the ejection phase is related to myocardial wall
thickening, and thus regional contractility.
All blood samples were collected on ice. Those to be analysed afterwards
were centrifuged at 4 ° C within 15 minutes after sampling to separate plasma
and then stored at - 70 ° C. Blood gas tensions were assessed with a blood gas
analyser (ABL 3, Radiometer, Copenhagen, Denmark). Haemoglobin content
(Hb) and oxygen saturation (O2sat) were assessed with a haemoximeter (OSM-
2, Radiometer). The O2 content (CaO2 in mmol L
-1) was calculated as Hb 
O2sat + 0.0102  PO2. From this, oxygen extraction was calculated for the
territory of myocardium perfused by the LAD,using a standard formula.To assay
plasma concentrations of norepinephrine, high performance liquid chromatog-
raphy with colometric electrochemical detection was used12,13. Plasma concen-
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trations of dexmedetomidine were analysed at the pharmacokinetics laboratory
of the Orion Corporation.
Statistical analysis
The drugs in the present study were investigated in each dog in the same
sequence.
Esmolol and dexmedetomidine were compared with their preceding control
values and with each other.To minimize a possible time-effect between esmolol
and dexmedetomidine measurements the values found during these measure-
ments were first substracted from their preceding control value before a statis-
tical comparison was made.
We used the non-parametric Wilcoxon signed rank test because of the rela-
tively small number of experiments. P value  0.05 was considered statistically
significant. Linear regression analysis was used to study the relation between the
change in haemodynamic indices of myocardial oxygen demand and change in
myocardial oxygen consumption. Data are presented as mean ± SEM, unless
stated otherwise.
Results
The dogs maintained normothermia throughout the study period, and shivering
was not observed.
The infusion regimens of esmolol and dexmedetomidine had sympatholytic
effects. Esmolol abolished the tachycardic response to isoprenaline in all dogs.
The dose of isoprenaline used to test the beta-adrenergic blockade was 0.45 ±
0.04 μg kg–1 . The infusion of dexmedetomidine resulted in plasma concentra-
tions of 1.1 ± 0.3 ng ml-1. Dexmedetomidine decreased plasma norepinephrine
concentration from 0.52 ± 0.15 nmol L–1 to 0.06 ± 0.03 nmol L-1 (P < 0.02).
Esmolol and dexmedetomidine decreased haemodynamic indices of myocar-
dial oxygen demand to a similar extend: esmolol decreased the RPP by 16 ± 3%
and the PWI by 16 ± 3%, dexmedetomidine decreased the RPP by 26 ± 3%
and the PWI by 16 ± 7% Fig. 2). However, these similar decreases in demand
resulted from different haemodynamic effects (fig 1). Dexmedetomidine had a
more pronounced bradycardic effect than esmolol (P= 0.01). The effects on
systolic aortic pressure were opposite with these two drugs: dexmedetomidine
increased systolic aortic pressure by 15 ± 4% whereas esmolol decreased systolic
aortic pressure by 8 ± 2% (P < 0.01). The increase in systolic aortic pressure
from dexmedetomidine was accompanied by a parallel increase in systemic
vascular resistance. The decrease in systolic aortic pressure from esmolol was
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Figure 1.The effects of esmolol and dexmedetomidine on;sympathetic tone,haemodynamic para-
meters and, indices of myocardial contractility in chloralose anaesthetized dogs.
Black bars indicate control values and grey bars values during the infusion of the respective drug.E:
esmolol;D:dexmedetomidine; HR:heart rate;AOP: aortic pressure; SVR: systemic vascular resis-
tance.
* : P < 0.05 vs. preceding control measurement; # : P< 0.05 esmolol vs. dexmedetomidine
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Figure 2. The effects of esmolol and dexmedetomidine on haemodynamic indices of myocardial
oxygen demand and on myocardial oxygen consumption, a direct measure of myocardial oxygen
demand, in chloralose anesthetized dogs.
Black bars indicate control values and grey bars values during the infusion of the respective drug.E:
esmolol; D: dexmedetomidine; PWI: pressure work index; RPP: rate pressure product.
* : P < 0.05 vs preceding control measurement; # : P< 0.05 esmolol vs dexmedetomidine
accompagnied by a decrease in indices of myocardial contractility, dPdtmax and
regional myocardial area decrease (Fig.1). The decrease in myocardial contrac-
tility after esmolol resulted in a marginal decrease in cardiac output compared to
Control 1 (12 ± 4% decrease, P = 0.05) but not compared to dexmedetomidine
(P = 0.17).
In contrast to their suppressive effect on haemodynamic indices of myocar-
dial oxygen demand, neither drug decreased measured myocardial oxygen
consumption (Fig. 2). To study this finding into more detail we plotted changes
in myocardial oxygen consumption as a function of changes in RPP and PWI
(haemodynamic indices of demand). No linear relationship was observed (Fig.
3).
Esmolol and dexmedetomidine maintained myocardial oxygen delivery by
different mechanisms (Table 1). Dexmedetomidine: increased blood haemo-
globin concentration, increased myocardial oxygen extraction, increased coro-
nary vascular resistance, and tended to decrease coronary flow (P = 0.13).
Esmolol maintained blood haemoglobin concentration and coronary flow, and
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Figure 3. The relation between changes(vs. preceding control value for each experiment) in
haemodynamic indices of myocardial oxygen demand and in myocardial oxygen consumption in
the presence of esmolol (Esmo) and in the presence of dexmedetomidine (Dexmed).
No significant linear relationship was found.
decreased coronary vascular resistance and myocardial oxygen extraction.
Neither drug affected coronary venous pH.
Thus, esmolol and dexmedetomidine decreased haemodynamic indices of
myocardial oxygen demand to a similar extent, but neither drug decreased
myocardial oxygen consumption, a direct measure of myocardial oxygen
demand.
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Table 1. The effects of esmolol and dexmedetomidine on determinants of myocardial oxygen
consumption and delivery in chloralose anaesthetised dogs.
Control 1 Esmolol Control 2 Dexmede-
tomidine
Arterial
Haemoglobin mmol L-1 8.2  0.3 8.3  0.3 7.7  0.2 9.0  0.4*#
pH 7.47 ± 0.02 7.44 ± 0.02* 7.40 ± 0.01 7.45 ± 0.03#
PO2 kPa 33.4 ± 5.8 30.3 ± 5.6 31.5 ± 5.6 35.7 ± 5.9
Oxygen content mmol L-1 8.3 ± 0.3 8.3 ± 0.2 7.8 ± 0.3 9.3 ± 0.4* #
PCO2 kPa 4.1 ± 0.2 4.2 ± 0.2 4.2 ± 0.1 4.3 ± 0.2
Coronary venous
pH 7.40  0.02 7.39  0.02 7.35  0.02 7.39  0.03
PO2 kPa 2.5  0.1 3.0  0.2
* 3.2  0.2 2.8  0.2*#
O2 content mmol L
-1 2.4 ± 0.2 3.0 ± 0.2* 2.9 ± 0.2 3.0 ± 0.2#
Coronary blood flow
ml min-1 100g-1
76  10 78  10 80  11 69  14
Myocardial oxygen delivery
mmol min-1100g-1
0.63  0.07 0.65  0.09 0.63  0.10 0.61  0.10
Arterial-coronary venous oxygen content
difference mmol L-1
5.9 ± 0.3 5.3 ± 0.3* 4.9 ± 0.3 6.3 ± 0.4*#
Myocardial oxygen extraction ratio 0.71  0.02 0.64  0.03* 0.63  0.03 0.67  0.02*#
Myocardial oxygen consumption
mmol min-1 100 g-1
0.45  0.05 0.43  0.06 0.40  0.07 0.42  0.07
Coronary vascular resistance
mmHg ml-1 min-1 100g-1
1.77  0.25 1.57  0.22* 1.62  0.27 2.32  0.43*#
Discussion
Profylactic administration of sympatholytic drugs during the emergence period
may decrease myocardial ischaemia in certain groups of patients. Theoretically,
this beneficial effect is, at least partly, related to their effect on myocardial oxygen
demand. The peripherally acting beta-blockers and centrally acting alpha2 -
agonists are two fundamentally different classes of sympatholytic drugs but their
effects on myocardial oxygen demand have not been compared directly. There-
fore, we studied in 11 chloralose anaesthetised dogs if a beta blocker and an
alpha2 agonist have different effects on myocardial oxygen demand and on
frequently used haemodynamic indices of myocardial oxygen demand.
An important finding in this study is that both classes of sympatholytic drugs
decreased haemodynamic indices of myocardial oxygen demand to a similar
extent but did not decrease myocardial oxygen consumption. In this study
myocardial oxygen consumption reflected myocardial oxygen demand because
the dogs had an unlimited coronary blood flow.
A possible explanation for this finding is that myocardial oxygen consump-
tion measurements may not have been completely accurate. In previous pilot
experiments, we observed that measurements of myocardial blood flow using a
flow probe and methylene blue to delineate the perfusion area, underestimates
myocardial blood flow as measured with microspheres, a gold standard of blood
flow measurement. However, the percentage of error was small, systematic and
stable. Therefore we concluded that myocardial blood flow measurements using
a flow probe can accurately detect a change in oxygen delivery.
A more likely explanation for the discrepancy between myocardial oxygen
consumption and haemodynamic indices of myocardial oxygen demand in the
current study may be the inaccuracy of haemodynamic indices in predicting
myocardial oxygen demand. We studied RPP and PWI because these two
indices can be easily calculated in clinical practice from heart rate, systolic pres-
sure and cardiac output. They have been shown to correlate with myocardial
oxygen consumption in chloralose anaesthetised dogs9and in humans14.
However, it has been argued that the conclusions from these studies may be false
because of methodological pitfalls such as pooling of all data instead of using
only single data points for each subject15. An explanation for the inaccuracy of
haemodynamic indices in predicting myocardial oxygen demand may be that
they were primarily developed as a clinical useful indices and thus do not
include all parameters determining myocardial oxygen demand9.
So, we may conclude that neither dexmedetomidine nor esmolol decreased
myocardial oxygen demand in the present comparative study in chloralose
anaesthetized dogs. This finding is in accordance with previous non-compara-
tive studies. Studies from our laboratory showed that dexmedetomidine does
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not affect myocardial oxygen consumption in anaesthetized dogs and goats16-18
and Sidi et all19,20 showed that esmolol does not affect myocardial oxygen
demand in anaesthetized dogs19,20
Another important finding in the present comparative study is that the beta
blocker and the alpha2 agonist had different haemodynamic effects. Esmolol
decreased both blood pressure and heart rate. Dexmedetomidine increased
blood pressure, but decreased heart rate to a greater extend than esmolol. The
decrease in arterial pressure from esmolol seemed to result from its
cardiodepressive effects, because esmolol suppressed indices of myocardial
contractility without affecting the systemic vascular resistance. Hypotension is a
known adverse effect of esmolol and is not fully explained by its beta receptor
blocking effect21. The decrease in myocardial contractility from esmolol in the
present study is in accordance with previous studies in which doses of more than
300 μg kg-1 min-1 were used 22-24. The effects of esmolol on peripheral vascular
resistance are equivocal; both an increase23 and no effect25have been observed.
Dexmedetomidine infusion was associated with an increase in blood pressure
and systemic vascular resistance. Generally, dexmedetomidine infusion results in
biphasic changes in blood pressure. Initially, blood pressure increases for a short
period (i.e. less than 20 minutes). This pressor phase is caused by stimulation of
alpha2 -adrenergic receptors in peripheral vessel walls. Over time the central
sympatholytic effects predominate with a decline in blood pressure7,26. In the
present study, blood pressure was still significantly increased approximately one
hour after starting the infusion of dexmedetomidine, despite a significant
decrease in plasma norepinephrine concentration. This implies a much longer
duration of the vasoconstrictive phase which may be explained by the species
studied and by the anaesthetic technique used in our experiments. It has been
shown that the peripheral vasoconstrictive effect of dexmedetomidine is more
pronounced in dogs than in humans27,28. The importance of the anaesthetic
technique when studying the effects of dexmedetomidine were already pointed
out in a previous study from our laboratory18. In the present study, we used α-
chloralose anaesthesia because it is known to have no major effect on central
neuroregulation and on oxygen metabolism29,30. However, α-chloralose is also
known to potentiate the pressor effects of alpha2 agonists
31.
The heart rate lowering effect of dexmedetomidine was more pronounced
than that of esmolol. In accordance, a case of tachycardia in a cardiac surgical
patient has been reported which was unresponsive to esmolol but resolved after
dexmedetomidine32. The ability of alpha2-agonists to decrease heart rate has
been attributed to their central sympatholytic effect, as well as to a decrease in
norepinephrine release at the peripheral neuroeffector junction33. The more
pronounced bradycardic effect of dexmedetomidine suggests that an additional
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vagomimetic effect may be involved in producing bradycardia. This is because
the heart rate reduction induced by almost complete beta1-receptor blockade
during esmolol infusion was the maximum which could be obtained from
sympatholysis alone. It could be argued that the infusion protocol of esmolol in
the present experiments did not result in adequate beta1-receptor blockade.
However, baseline plasma norepinephrine concentrations, and thus beta-
adrenergic stimulation,were low in these chloralose anaesthetized dogs.Also,we
used 0.45 ± 0.04 μg kg-1 of isoprenaline to test beta1-adrenergic blockade, this is
in the higher range of the doses of isoprenaline used in other studies on the
beta-blocking effects of esmolol, e.g. 0.125 - 0.5 μg kg-1 34-36. Third, it has been
shown that the infusion of only one third of the dose of esmolol used in the
current study already blocks 70% of the cardiac beta1-receptors
36.
Esmolol and dexmedetomidine did not affect myocardial oxygen consump-
tion, however they affected coronary vascular resistance and the relative contri-
bution of the individual parameters of myocardial oxygen delivery. Esmolol
decreased myocardial oxygen extraction and coronary vascular resistance
(CVR) which suggests that esmolol has coronary vasodilating properties. In
contrast, dexmedetomidine increased fractional oxygen extraction and CVR16-
18. It has been suggested that these effects of dexmedetomidine indicate that its
alpha2-adrenergic coronary vasoconstrictive effects result in a relative shortage
of oxygen delivery7. However, our findings indicate a possible alternative expla-
nation. Dexmedetomidine increased myocardial oxygen extraction secondary
to an increase in haemoglobine and arterial O2 content, and not secondary to a
decrease in coronary venous O2 content. Indications that the increase in
myocardial oxygen extraction was not associated with a critical shortage of
myocardial oxygen delivery when giving dexmedetomidine are:
1. oxygen extraction was still far below maximal37
2. coronary venous pH did not decrease
3. dexmedetomidine suppressed haemodynamic indices of myocardial oxygen
demand.
Conversely, the observed increase in arterial O2 content and myocardial oxygen
extraction from dexmedetomidine did not increase myocardial oxygen delivery
because coronary blood flow tended to decrease.
The increase in haemoglobin from dexmedetomidine is an interesting feature
of this study. The most likely explanation for this finding is that alpha2-receptor
activation from dexmedetomidine caused recruitment of erythrocytes from
splenic stores. A previous study in dogs showed the effects of alpha-
adrenoreceptor activation on the splenic capsule and splanchnic capacitance
vasculature38, and there is evidence that these effects are alpha2-receptor rather
than alpha1-receptor mediated
39. Also in humans alpha-adrenergic induced
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blood volume shifts from the spleen and increases in hematocrit have been
described40,41. Another possible explanation for the increase in haemoglobin
concentration is a transcapillary fluid shift from the intravascular space in those
organs were venous vasoconstriction outstands arterial vasoconstriction. This
mechanism has already been demonstrated in rats42. We believe that this expla-
nation is less likely, because the expected decrease in end-diastolic pressure asso-
ciated with a fluid shift, was not observed in our experiments. The increase in
haemoglobin concentration associated with the administration of
dexmedetomidine can also, at least in part, explain the measured increase in
coronary vascular resistance. This is because viscosity, of which haematocrit is
the major determinant, contributes to vascular resistance43.
A limitation of this study is that the results obtained are restricted to dogs;
there may be relevant species difference in the effect of sympatholytic drugs on
myocardial oxygen consumption.However, myocardial oxygen consumption in
the current study was similar to that reported in awake and in anaesthetized
humans14.
A methodological limitation of the current study is that the drugs were
always investigated in the same sequence in each experiment; first esmolol, then
dexmedetomidine. This was done because of the relatively long plasma half-life
of dexmedetomidine (2 hours) compared to the very short plasma half-life of
esmolol (9 minutes). However, we applied statistical methods to minimize the
possible time effect associated with a sequential study design.
A final limitation is that we studied only one dose of each drug and therefore
cannot exclude that higher doses are needed to decrease myocardial oxygen
consumption. However, the dose used resulted in adequate sympatholysis for
each drug.
In conclusion, peripheral sympatholysis from a beta blocker and central
sympatholysis from an alpha2-agonist decrease haemodynamic indices of
myocardial oxygen demand to a similar extend, but do not decrease myocardial
oxygen consumption in chloralose anaesthetized dogs.
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CHAPTER 6
The effects of esmolol and dexmedetomidine
on myocardial oxygen consumption during
sympathetic stimulation in dogs
Henriëtte M. Willigers, Frits W. Prinzen and Paul M.H.J. Roekaerts.
J Cardiothorac Vasc Anesth 2006; 20: 364-70. With small modifications.
87
Abstract
Objective: To compare the potential of the β1-adrenergic receptor blocker
esmolol and the α2-adrenergic receptor agonist dexmedetomidine to suppress
the cardiovascular and neuro-endocrine response to a sympathetic stimulus
Design: Experimental study.
Setting: Laboratory of University.
Participants: Eleven anesthetized dogs.
Interventions: Catheters for arterial and coronary venous blood sampling and
calculation of myocardial oxygen consumption were inserted. Pressure sensors
were placed in the aorta, in the left ventricle and in a carotid artery. Flow probes
were placed around the aortic root and around the left anterior descending
coronary artery. Esmolol was infused (loading dose 1 mg/kg, infusion 0.3 mg-
1.kg-1.min-1.), and the adequacy of β-blockade was checked. Dexmedetomidine
infusion was started more than 30 minutes after stopping esmolol (loading dose
dexmedetomidine 1 μg/kg, infusion 1.5 μg-1.kg-1.h-1). Occlusion of both
carotid arteries was used as a sympathetic stimulus before and during infusion of
esmolol and before and during infusion of dexmedetomidine.
Measurements and Main Results: The variables were measured just before
and during sympathetic stimulation, and changes were calculated. Both drugs
suppressed the increase in dPdTmax. Dexmedetomidine suppressed the increase
in plasma norepinephrine; and the increase in systemic vascular resistance
(dexmedetomidine: 4 ± 4%, esmolol: 25 ± 19%; increase, P = 0.02). Esmolol
attenuated the heart rate response (esmolol: 2 ± 2% increase, dexmedetomidine:
20 ± 18% increase; P = 0.02). However, dexmedetomidine decreased baseline
heart rate more than esmolol; therefore, the absolute maximal heart rate during
sympathetic stimulation was lower in the presence of dexmedetomidine
(dexmedetomidine 119 ± 14, esmolol 141 ± 15 beats min–1; P = 0.01). Neither
drug suppressed the increase in myocardial oxygen consumption.
Conclusions: Both dexmedetomidine and esmolol have the potential to
suppress some of the cardiovascular and neuro-endocrine changes to a sympa-
thetic stimulus but neither drug suppressed the increase in myocardial oxygen
consumption.
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Introduction
Sympatholytic drugs such as beta-adrenergic blockers and alpha2-adrenergic
agonists have a beneficial effect on cardiac outcome in selected surgical
patients1,2, and therefore the American College of Cardiology / American Heart
Association guidelines recommend consideration of administration of one of
these drugs during the perioperative period3.One reason for the beneficial effect
of sympatholytic drugs on cardiac outcome is that they suppress the increase in
myocardial oxygen consumption associated with sympathetic stimulation. In
accordance, it has been shown that beta-blockade suppresses the increase in
myocardial oxygen consumption in exercising dogs4, and the alpha2-agonist
dexmedetomidine suppresses the increase in heart rate and myocardial lactate
release during emergence from anesthesia in dogs5.
To date, there are no comparative studies on the potential of beta-blockers
and alpha2-adrenergic agonists to decrease perioperative cardiac complications
6.
Clinical studies in which the sympatholytic potential of these drugs were
compared suggest that alpha2-agonists may be superior
7,8. This is because the
central acting alpha2-agonists attenuate the heart rate,blood pressure, and plasma
catecholamine response to sympathetic stimulation, whereas the peripheral
acting beta-blockers only attenuate the heart rate response. However, it remains
unknown if this more complete sympatholytic action of alpha2-agonists trans-
lates into a more complete suppression of the sympathetic mediated increase in
myocardial oxygen consumption. This is because myocardial oxygen consump-
tion was not measured in these studies.
Therefore the purpose of the current study was to compare the potential of
the alpha2-agonist dexmedetomidine and the beta1-blocker esmolol to suppress
the cardiovascular effects and the increase in myocardial consumption associated
with a sympathetic stimulus.Because of the invasive nature of the measurements
the study was done in anesthetised dogs. Carotid sinus hypotension from
bicarotid occlusion was used as a sympathetic stimulus because this is a well
known stimulus 9,10 and because it induced the most reliable and reversible
hemodynamic changes and increases in myocardial oxygen consumption of all
sympathetic stimuli tested in our pilot experiments. The other sympathetic
stimuli tested were; application of capsicain on the stomach11, in the knee12, and
on the epicardium13.
In each animal, the effects of esmolol and of dexmedetomidine on sympa-
thetic induced changes in: plasma norepinephrine levels, hemodynamic vari-
ables, hemodynamic indicices of demand, and myocardial oxygen consumption
were measured.
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Methods
Animal Preparation and Instrumentation
Eleven adult mongrel dogs (31 ± 6 kg) were studied with the approval of the
Animal Care Committee of the University. The dogs were anesthetized with
sodium thiopental 25 mg kg-1 intravenously; intubated, and ventilated with
oxygen 30% in nitrous oxide. Halothane (inspired concentration 1-1.5%) was
added to maintain hemodynamic stability during thoracotomy and instrumen-
tation.The rectal temperature of the dogs was kept between 37° C and 39° C by
means of a thermostatically regulated heating mattress and a warmed operating
room. Heart rate and rhythm were monitored using ECG lead II.
The chest was opened through the left fifth intercostal space and catheters
were inserted into the femoral artery and into the coronary vein accompagning
the left anterior descending (LAD) artery for arterial and left ventricular coro-
nary venous blood sampling respectively. Pressure sensors (Sentron 180 S,
Cordis, Roden, the Netherlands) were inserted through a femoral artery into
the ascending aorta and left ventricle.Ultrasonic transit-time flow probes (Tran-
sonic Systems, Ithaca, NY) were placed around the aortic root and around the
LAD artery just proximal to the first diagonal branch.A pulmonary artery cath-
eter (Baxter) was introduced via the right jugular vein into the pulmonary
artery and connected to a thermodilution cardiac output computer (Baxter
Edwards SAT 2, Irvine, CA) to compare cardiac output measurements derived
from the ultrasonic aortic flow probe with the thermodilution cardiac output
measurements.
To be able to induce reversible bicarotid occlusion, both common carotid
arteries were dissected free over a distance of 1.5 cm and care was taken to
ensure that nerve branches from the vagosympathetic trunk remained intact.
Umbilical tape was placed loosely around each carotid artery, and the two ends
of the ties were passed through stiff plastic tubing to form a snare occluder.
Carotid pressure distal to the occluder was measured with a catheter (Bardicath,
Bard Limited,Murray Hill, NJ) introduced into the cranial thyroid artery and
connected to a pressure transducer (Baxter 43-600F).
Study Protocol
As soon as instrumentation was completed, nitrous oxide and halothane were
discontinued. A loading dose of 40 mg kg-1 chloralose was administered,
followed by a maintenance infusion of 8 mg kg-1 h-1. The animals were venti-
lated with 30% oxygen in air to normocarbia. After a stabilization period of at
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least 60 minutes, 4 successive experimental conditions were studied in each dog
(fig.1).
Esmolol (Ohmeda Inc., NJ, USA) was given as a loading dose of 0.5 mg kg -1
min -1 for two minutes, followed by a continuous infusion of 0.3 mg kg-1 min-1.
To check that the beta1-adrenergic blockade from esmolol was adequate, the
response to the tachycardiac dose of isoprenaline was tested during the esmolol
infusion. The tachycardiac dose of isoprenaline was defined as the dose neces-
sary to increase heart rate by more than 20% during control 1.
Dexmedetomidine (Orion Corporation, Farmos Research, Turku, Finland)
was given as a loading dose of 1 μg kg -1 over twenty minutes, followed by a
continuous infusion of 1.5 μg kg -1 h -1 .With this infusion we aimed at a plasma
concentration of dexmedetomidine above 0.5 ng.mL-1 based on the
pharmacokinetic set in the STANPUMP software (Department of Anesthesia,
Stanford University, Palo Alto, CA)14.
Carotid sinus hypotension from bicarotid occlusion was used as a sympathetic
stimulus as described in previous studies9,10. Baseline measurements were
performed 20 minutes after start of each condition, and bicarotid occlusion
(BCO) measurements were performed after maximum changes from BCO had
stabilized, which was approximately after one minute of occlusion.
The following variables were measured:
1. Carotid pressure distal to the occlusion.
2. Hemodynamic indices: heart rate, aortic pressure, left ventricular pressure,
and cardiac output.
3. Plasma concentration of norepinephrine.
4. Variables related to left ventricular myocardial oxygen metabolism: LAD
coronary venous blood gases, LAD coronary flow, and arterial blood gases
and hemoglobin content.
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Figure. 1. The study protocol in 11 chloralose-anesthetized dogs. BL, baseline; BCO, bicarotid
occlusion; Esmo, esmolol; Dex, dexmedetomidine.
To calculate LAD flow relative to myocardial weight, the perfusion area of the
LAD was delineated by injecting methylene blue dye in the LAD at the end of
each experiment15. Then, the dogs were killed by a pentobarbital overdose and
their hearts were excised. The methylene-blue stained portion of the heart was
dissected and weighed.
Data Analysis
All hemodynamic and coronary flow signals were preamplified and then digi-
tized with a 16-channel, 12-bit A/D interface in an IBM-compatible PC.
Sampling frequency was 200 Hz for each channel. The signals were continu-
ously displayed on the computer screen during the experiment and beat-to-beat
values were stored on the hard disk during each period of measurement. From
these values the mean value over a stable hemodynamic period of two minutes,
i.e. less than 5% heart rate variation,was calculated afterwards.Peak of first deriv-
ative of left ventricular pressure (LV dPdtmax) was derived from the left ventric-
ular pressure signal. Systemic vascular resistance (SVR) was calculated as the
quotient of mean aortic pressure and mean aortic blood flow.Coronary vascular
resistance (CVR) was calculated as the quotient of mean aortic pressure and
mean coronary blood flow.
The Rate Pressure Product (RPP),which is a frequent used index of myocar-
dial oxygen demand, was calculated as; RPP = heart rate × systolic aortic pres-
sure.
Arterial plasma norepinephrine concentrations were analyzed with high
performance liquid chromatography with colorimetric electrochemical detec-
tion16,17. Plasma concentrations of dexmedetomidine were determined by gas
chromatography-mass spectrometry18 at Farmos research, Turku, Finland. All
blood samples were collected on ice. Those to be analyzed afterwards were
centrifuged at 4 ° C within 15 minutes after sampling and stored as plasma at
–70° C. Arterial and coronary venous blood gas tensions were assessed with a
blood gas analyzer (ABL 3, Radiometer, Copenhagen, Denmark). Hemoglobin
content (Hb) and oxygen saturation (O2sat) were assessed with a hemoxymeter
(OSM-2, Radiometer). The O2 content ( in mmol L
–1) was calculated as Hb ×
O2sat + 0.0102 × PO2. From this, oxygen extraction was calculated for the
territory of myocardium perfused by the LAD, using a standard formula.
Statistical Analysis
The focus of the current study was on the effect of sympatholytic drugs on
sympathetic induced cardiovascular responses. Therefore BCO-induced
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responses were calculated as the difference between the value measured during
BCO and the baseline value, and from this the percentage change from baseline
was also calculated. Responses in presence of esmolol or dexmedetomidine
were compared to each other and to their preceding control responses.A meth-
odological limitation of the study was that the drugs always had to be investi-
gated in the same sequence in each experiment because of the very short plasma
half-life of esmolol and the long plasma half-life of dexmedetomidine. To mini-
mize a possible time-effect of the comparison between esmolol and
dexmedetomidine, the corresponding control values were first subtracted from
the values found in presence of esmolol or dexmedetomidine. Based on our
pilot experiments the present study was powered to detect a suppression of the
BCO mediated increase in myocardial oxygen consumption of minimally 50%
(power: 0.80 and α = 0.05). Because of the number of experiments were too
few to presume a standard distribution the non-parametric Wilcoxon signed
rank test was used as a statistical test.Data are presented as mean  standard devi-
ation, unless stated otherwise.
Results
Baseline experimental conditions
Throughout the study period, all dogs maintained body temperature and shiv-
ering was not observed. Dexmedetomidine infusion resulted in plasma concen-
tration of dexmedetomidine of 1.1 ± 0.9 ng ml –1 .
The change in baseline values from administration of dexmedetomidine or
esmolol (Table 1) has been discussed in a previous publication19. The infusion
protocols used resulted in sympatholysis because dexmedetomidine decreased
plasma norepinephrine concentration more than 80% (table 1) and esmolol
abolished the tachycardic response to isoprenaline in all experiments. The mean
tachycardic dose of isoprenaline used to test the beta-adrenergic blockade was
0.45 ± 0.04 μg kg-1. Esmolol did not decrease the baseline plasma
norepinephrine concentration.
Effect of Bicarotid Occlusion during Control Conditions
An example of the effect of BCO during control conditions is plotted in figure
2. Occlusion of the carotid arteries resulted in a significant decrease in carotid
pressure (Control 1; decrease 22 ± 11%, Control 2; decrease 15 ± 8% (P = 0.12,
Control 1 vs Control 2). Simultaneously, plasma norepinephrine concentration,
heart rate, systolic aortic pressure, SVR, dPdTmax, RPP, coronary flow and
myocardial oxygen consumption increased (Fig. 3 and 4, grey bars). The effects
of BCO were not statistically different between both control measurements,
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Table 1: Baseline values (Mean ± SD) measured just before sympathetic stimulation during each
experimental condition in chloralose anesthetized dogs.
Variable Control 1 Esmolol Control 2 Dexmede-
tomidine
Heart rate
beats min-1
160 ± 20 138 ± 13* 150 ± 18 101 ± 20*#
Systolic aortic pressure
mm Hg
127 ±20 127 ± 18 128 ± 12 139 ± 25
dPdTmax
mmHg sec-1
2093 ± 347 1442 ± 276* 1706 ± 285 1465 ± 265*#
Cardiac output
L min-1
4.2 ± 1.9 2.7 ± 1.0* 2.8 ± 0.9 2.0 ± 0.7*
Systemic vascular resistance
mmHg min. L-1
37 ± 22 51 ± 16 50 ± 18 76 ± 32*
Pressure work index
mmol min-1 100g-1
0.67 ± 0.16 0.52 ± 0.09* 0.56 ± 0.08 0.45 ± 0.07*
Rate pressure product
mmHg beats min-1
20270 ± 3272 17556 ± 3254* 19176 ± 2876 13823 ± 2261*
Norepinephrine
nmol L -1
0.36 ± 0.24 0.50 ± 0.37 0.67 ± 0.55 0.11 ± 0.15*#
O2 consumption
mmol min–1100g-1
0.44 ± 0.11 0.38 ± 0.14 0.38 ± 0.15 0.35 ± 0.11
Coronary flow
mL min–1100g-1
85 ± 23 72 ± 26 71 ± 24 52 ± 17
Coronary vascular resistance
mm Hg ml–1 min–1 100g -1
1.69 ± 0.98 1.94 ± 0.79 1.98 ± 0.88 2.92 ± 1.43#
* P < 0.05 esmolol or dexmedetomidine compared to preceding control; # P < 0.05 esmolol
compared to dexmedetomidine.
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Figure.2.Representative recordingsof the effects of bicarotid occlusion (BCO) inone of the dogs.
except for heart rate which increased more ( P = 0.01) and for SVR ( P = 0.03)
which increased less during Control 1 than during Control 2.
Thus, during control conditions BCO stimulated the sympathetic nervous
system and this resulted in a parallel increase of myocardial oxygen consumption
and hemodynamic indices of myocardial oxygen demand.
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Figure 3. Bar graphs showing the effect of bicarotid occlusion as a sympathetic stimulus on heart
rate,SVR,dPdTmax,and norepinephrine plasma concentrations in anesthetized dogs.Data repre-
sent percentage changes (mean  standard error) during both control measurements (C1,C2;grey
bars) and in presence of esmolol or dexmedetomidine (Esmo,Dex;black bars).* P< 0.05;esmolol or
dexmedetomidine versus preceding control measurement.# P < 0.05 esmolol versus dexmedeto-
midine measurement.
Effect of Bicarotid Occlusion in Presence of Esmolol and Dexmedetomidine
Esmolol and dexmedetomidine had different effects on several sympathetic
mediated hemodynamic responses. (black bars, Fig. 3 and 4). First, esmolol, but
not dexmedetomidine, attenuated the increase in heart rate (P = 0.02, esmolol
vs dexmedetomidine). However, the absolute maximal heart rate during BCO
was lower in presence of dexmedetomidine (dexmedetomidine 119 ± 14,
esmolol 141 ± 15 beats min–1; P = 0.01). This can be explained was because
dexmedetomidine reduced the baseline heart rate more than esmolol (Table 1).
In contrast,dexmedetomidine but not esmolol suppressed the increase in plasma
norepinephrine concentration and the increase in SVR (Fig. 3). Both drugs
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Figure 4. Bar graphs showing the effect of bicarotid occlusion as a sympathetic stimulus on the
Rate Pressure Product, myocardial oxygen consumption, flow in LAD coronary artery, and coro-
nary vascular resistance in anesthetized dogs.Data represent percentage changes (mean  standard
error) during both control measurements (C1, C2; grey bars) and in presence of esmolol or
dexmedetomidine (Esmo, Dex; black bars). * P< 0.05; esmolol or dexmedetomidine versus
preceding control measurement. # P < 0.05 esmolol versus dexmedetomidine measurement.
suppressed the increase in dPdTmax (P = 0.16, esmolol vs dexmedetomidine) .
However, despite their effects on hemodynamic responses; neither esmolol nor
dexmedetomidine suppressed the sympathetic mediated increase in myocardial
oxygen consumption and coronary flow. Simultaneously, coronary vascular
resistance remained unchanged during BCO in presence of esmolol but
decreased in presence of dexmedetomidine (P= 0.03 esmolol vs dexmede-
tomidine). Myocardial oxygen extraction remained unaffected (data not
shown).
Thus, dexmedetomidine but not esmolol suppressed the BCO-related
increase in plasma norepinephrine concentration and SVR. In contrast, esmolol,
but not dexmedetomidine, suppressed the increase in heart rate. However,
neither drug suppressed the increase in myocardial oxygen consumption.
Discussion
In this study in dogs we compared the potential of a beta1- blocker and an
alpha2- agonist to suppress the hemodynamic changes and increase in myocar-
dial oxygen consumption associated with a sympathetic stimulus. The results of
the current study confirms and extends findings of previous studies.Although in
different ways, both drugs, at a sympatholytic dose, suppressed hemodynamic
responses to sympathetic stimulation. However, neither drug affected the
increase in myocardial oxygen consumption associated with a sympathetic stim-
ulus to a significant extend.
Until now, few studies have compared the effects of a beta-blocker and an
alpha2-agonist on the hemodynamic and neuroendocrine consequences of a
sympathetic stimulus. In these studies, the alpha2-agonist clonidine suppressed
the sympathetic mediated increase in blood pressure and in plasma catechol-
amines better than the beta-blocker esmolol7,8, which is in accordance with our
findings. In contrast to our findings, clonidine suppressed the heart rate response
to a similar extend as the beta-blocker. This discrepancy in findings may be the
result of different measurements: indeed, in one of these studies20, not the heart
rate response, but the maximal heart rate in presence of an alpha2-agonist was
measured. This heart rate was found to be lower than the maximal heart rate
during control which is also in accordance with the current findings. Further-
more, these studies differed from the present experiments in several essential
ways; they were performed in humans, inhalation anesthesia was used, the less
selective alpha2-agonist clonidine was studied, and the stress stimuli used in these
studies were “intubation” and “increase in desflurane concentration”.
It is not likely that the maintained heart rate response in presence of
dexmedetomidine resulted from an increase in sympathetic tone. First; this is
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because the plasma concentration of norepinephrine did not increase, and
second; the maximal heart rate remained lower than the maximal heart rate in
presence of beta1-blockade. We hypothesize that the increase in heart rate
during sympathetic stimulation in presence of dexmedetomidine resulted from
a decrease of an increased parasympathetic tone. In accordance with
parasympathicomimetic effects of dexmedetomidine, a study in dogs showed
that the vagus nerve plays an important role in the anti-arrhythmic effects of
dexmedetomidine21.
The current study extends the findings of previous studies because the effects
of a beta-blocker and an alpha2-agonist on sympathetic mediated increases in
myocardial oxygen consumption were measured in addition to changes in
hemodynamic variables. We found that, despite suppression of several
hemodynamic responses, neither esmolol nor dexmedetomidine suppressed the
increase in myocardial oxygen consumption associated with a sympathetic stim-
ulus. There are several possible explanations for this finding.
First, the sympathetic stimulus could be too weak. In the current study
carotid hypotension from bicarotid occlusion was used as a sympathetic stimulus
which increased the rate-pressure-product by 40% and the myocardial oxygen
consumption by approximately 30%. In accordance, previous work from our
laboratory has shown that the decrease in myocardial energy requirements from
dexmedetomidine depends on baseline heart rate and blood pressure22. Also, it
has been shown that beta-blockade blunts the increase in myocardial oxygen
consumption in exercising dogs4 but it does not suppress the increase in myocar-
dial oxygen consumption related to administration of cocaine in conscious dogs
23. In accordance with these experimental studies in animals, a study in humans
showed that beta-blockade had unpredictable effects on myocardial ischemia
from mental-stress24, but reliably reduced myocardial ischemia from exercise-
stress. Exercise is one of the most severe physiologic stressors for the cardiovas-
cular system increasing the rate-pressure-product and myocardial oxygen
consumption more than 150% 25,26, and it has been shown that betablockade
limits the exercise induced increase in myocardial oxygen consumption by
reducing increases in heart rate and in myocardial contractility 25. Cocaine
increased the rate-pressure-product by only 70% 23 indicating that this stimulus
has less hemodynamic consequences than exercise. However, measuring the
effects of sympatholytic drugs on a stimulus which does not result in a large
hemodynamic response seems to be clinically relevant because mental activities
are as potent as physical activities in triggering daily life ischemia27.
A second possible explanation for the lack of effect of dexmedetomidine and
esmolol on myocardial oxygen consumption was that the present study was not
powered to detect a suppression of the BCO related increase in myocardial
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oxygen consumption of less than 50% Therefore it cannot be excluded that
esmolol and dexmedetomidine supressed sympathetic mediated increases in
myocardio oxygen consumption to a lesser extend.
A final explanation may be that the doses of esmolol and dexmedetomidine
used were not adequate. However, the infusion regimens of both esmolol and
dexmedetomine resulted in adequate sympatholysis in all experiments, as
evidenced by blunting the isoprenaline-mediated tachycardic response and the
significant decrease in plasma norepinephrine concentrations, respectively. Also,
infusion of one-third of the dose of esmolol used in the current study blocked
70% of the beta-receptors in another study28, and a plasma concentration of
dexmedetomidine above 0.5 ng.mL-1 is known to reduce sympathetic tone
effectively in dogs29 and in humans30.
The current complex experimental study enabled comparison of the effects
of a beta1-blocker and an alpha2-agonist on sympathetic mediated changes in
coronary hemodynamics. In presence of dexmedetomidine, sympathetic stimu-
lation induced a decrease in coronary vascular resistance indicating that
dexmedetomidine maintains adaptive coronary vascular responses to an increase
in myocardial oxygen demand.Alpha2-agonists have been shown to enhance the
release of endothelium –derived relaxing factor (ERDF) in the coronary circu-
lation31, but ERDF was not measured in the current study. It could be argued
that a shortage of myocardial oxygen supply explains the sympathetic mediated
decrease in CVR in presence of dexmedetomidine. However, we found no
indication for this because myocardial oxygen extraction and coronary venous
PH remained unchanged.
In contrast to the decrease in CVR in presence of dexmedetomidine, the
sympathetic mediated increase in coronary flow was associated with an
unchanged CVR in presence of esmolol. In a previous study CVR increased
during sympathetic stimulation in presence of betablockade 4. However, in that
study a non-selective beta blocker was studied in contrast to the beta1-adreno-
receptor antagonist studied in the current study.
The results of this study must be interpreted within the constraints of several
limitations. First, extrapolation of these data from dogs to humans should be
undertaken with caution.Second, a time effect in addition to a pharmacological
effect on the BCO-response can not be excluded. However, BCO had similar
effects for most variables during both control measurements and we applied
statistical methods to minimize a possible time-effect. Finally, anesthesia may
have influenced our measurements. However, chloralose anesthesia was used
because this is known to have relatively little influence on central neuro-
regulation32 and oxygen metabolism33.
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In summary, the effects of dexmedetomidine and esmolol on the neuro-
humoral and hemodynamic consequences of sympathetic stimulation in
chloralose-anesthetized dogs were in accordance with their respective central
and peripheral sympatholytic actions. However, neither drug had a significant
effect on the increase in myocardial oxygen consumption and coronary flow
associated with the applied sympathetic stimulus.
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Abstract
Background: Beta-blockers and alpha2-agonists decrease cardiac complica-
tions partly from their effects on baroreceptors. However, these effects have not
been compared directly.
Methods: Sequential measurements were performed in chloralose-anaesthe-
tized dogs during: Control 1, Esmo (esmolol (beta1-blocker)), Control 2, and
Dexmed (dexmedetomidine (alpha2-agonist)).We measured: 1) Heart Rate and
Arterial Pressure Variability (HRV and APV) using fast Fourier transformation,
2) plasma norepinephrine and arterial pressure response (pressure gain) to a
decrease in carotid artery pressure, and 3) the linear HR-pressure relationship to
changes in aortic pressure (cardiac baroreflex sensitivity), and minimal and
maximal HR plateau.
Results: Both sympatholytic drugs suppressed the maximal HR plateau.
Compared to Esmo, Dexmed: 1) maintained the cardiac baroreflex sensitivity
better (slope: -0.7 (0.3) versus -0.1 (0,2) (bpm/mmHg), P = 0.02), 2) increased
the (vagal) high frequency component of HRV (62 (17) versus 43 (17) dB, P =
0.05), 3) lowered the minimal HR plateau (77 (8) versus 126 (18) bpm), P =
0.02), and 4) decreased the low frequency component of APV (54 (8) versus 61
(11) dB,P = 0.02). In contrast Esmo tended to maintain the pressure gain better
than Dexmed (1.35 (0.92) versus 0.59 (0.67), P= 0.07).
Conclusions: Dexmed and Esmo have similar cardiac sympatholytic effects
but Dexmed has an additional vagomimetic and vascular sympatholytic effect.
As a result Dexmed maintains cardiac baroreflex sensitivity at lower heart rates
and improves arterial pressure stability, but Esmo maintains baroreceptor-medi-
ated vasoconstriction.
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Introduction
The mechanisms by which sympatholytic drugs decrease postoperative cardiac
complications are still being explored. There are indications from animal1 and
human research2 that these drugs improve myocardial oxygen balance from their
ceiling effect on sympathetic mediated tachycardic and hypertensive responses.
Recently, evidence has emerged that their effects on autonomic nervous system
mediated cardiovascular control may also be important in decreasing cardiac
complications3.This is because impaired cardiovascular control,which is known
to occur after surgery4, is a predictor for adverse cardiac outcome in certain
groups of patients5. The use of either a beta-adrenergic blocker or an alpha2-
adrenergic agonist is advised for pharmacological perioperative sympatholysis6.
This is because it remains unknown which of these groups of sympatholytic
drugs is superior in decreasing cardiac complications. To our knowledge, also
differences in baroreceptor mediated cardiovascular control of these groups of
drugs have not been studied. Our hypothesis is that beta-blockers and alpha2-
agonists have different effects on baroreceptor mediated cardiovascular control
because of their respective peripheral and central modes of action.Therefore,we
compared esmolol, a short acting beta1-blocker, to dexmedetomidine, the most
specific alpha2-agonist available, within chloralose-anaesthetized dogs. Auto-
nomic nervous system tone and baroreceptor mediated cardiovascular control
was evaluated from; the power of frequency spectra of heart rate and aortic pres-
sure variability,plasma norepinephrine concentrations, the response to a decrease
in carotid artery pressure, and cardiac baroreflex sensitivity.
Materials and methods
Instrumentation
Eleven adult Mongrel dogs (31(7) kg) were studied with the approval of the
Animal Care and Use Committee at the University of Maastricht, the Nether-
lands. The current study was part of our previous study focussing on the effects
of esmolol and dexmedetomidine on sympathetic mediated increases in
myocardial oxygen consumption 7.Details of instrumentation in these dogs have
been described in our previous paper. In short; anaesthesia was induced with
sodium thiopental 25 mg kg-1 intravenously, the trachea was intubated and the
lungs were ventilated with 30% oxygen in nitrous oxide. Anaesthesia was main-
tained with halothane (inspired concentration 1-1.5%). The rectal temperature
of the dogs was kept between 37° C and 39° C by means of a thermostatically
regulated heating mattress. Heart rate and rhythm were monitored using limb
lead II of the electrocardiogram. To monitor aortic and left ventricular pressure,
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pressure sensors (Sentron 180 S, Cordis, Roden, the Netherlands) were inserted
through the right femoral artery into the left ventricle and ascending aorta.
Ultrasonic transit-time flow probes (Transonic Systems, Ithaca, NY) were
placed around the aortic root and around the LAD artery. Catheters were
inserted into the femoral artery and into the left anterior descending (LAD)
coronary vein for arterial and coronary venous blood sampling respectively.
Both common carotid arteries were dissected free, taking care that nerve
branches from the vagosympathetic trunk remained intact. Umbilical tape was
placed loosely around each carotid artery and the two ends of the ties were
passed through stiff plastic tubing to form a snare occluder. Carotid pressure
distal to the occluder was measured with a catheter (Bardicath, Bard Limited)
introduced into the cranial thyroid artery and connected to a pressure trans-
ducer (Baxter 43-600F). Balloon tipped catheters (8 Fr, occlusion balloon cath-
eter, Medi-tech, Boston Scientific Cooperation) were introduced into the
femoral artery and vein and pushed up into the descending aorta and inferior
caval vein respectively to change the arterial pressure for evaluation of cardiac
baroreflex sensitivity.
Protocol
Once surgery was complete,nitrous oxide and halothane were discontinued and
chloralose (bolus: 40 mg kg-1, maintenance 8 mg kg-1 h-1) was infused intrave-
nously. After a stabilization period of at least 60 minutes measurements were
performed during the following sequential experimental conditions in each
dog: Control 1, Esmo (during esmolol infusion), Control 2, and Dex (during
dexmedetomidine infusion). This sequence was chosen because esmolol has a
much shorter half live than dexmedetomidine (9 minutes versus 2.3 hours).
Esmolol (Ohmeda Inc., NJ,USA) was given as a loading dose of 1 mg kg-1 in
two minutes, followed by an infusion of 0.3 mg kg–1 min-1. To check that the
beta1-adrenergic blockade from esmolol was adequate, the response to the
tachycardiac dose of isoprenaline was tested during the esmolol infusion. The
tachycardiac dose of isoprenaline was defined as the dose necessary to increase
heart rate by more than 20% during control 1.
Dexmedetomidine (Orion Corporation, Farmos Research, Turku, Finland)
was given as a loading dose of 1 μg kg-1 over twenty minutes, followed by a
continuous infusion of 1.5 μg kg-1 h–1.
The study protocol is shown in figure 1. At least 20 minutes after the start of
each experimental condition different tests of baroreceptor function were done.
First, arterial pressure and heart rate data of a stable hemodynamic period of at
least five minutes were stored for off-line spectral analysis of spontaneous heart
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rate and aortic pressure variability, as measures of cardiac autonomic balance and
arterial pressure stability .Then, the effect of a decrease in carotid artery pressure
from bilateral carotid artery occlusion on aortic pressure, and plasma
norepinephrine concentration was measured to evaluate the efferent sympa-
thetic vascular effects of baroreceptor stimulation. Finally, the effect of arterial
pressure variation on the heart rate response was measured to test cardiac
baroreceptor sensitivity. At the end of the protocol the dogs were killed by an
overdose of pentobarbital.
Data analysis and measurements
Hemodynamic data
All hemodynamic signals were preamplified and then digitized with a 16-
channel, 12-bit A/D interface in an IBM-compatible PC. Sampling frequency
was 200Hz for each channel. Beat-to-beat values of hemodynamic data were
stored on the hard disk during each period of measurement for off line analysis.
Spontaneous Heart Rate Variability (HR Variability) and Aortic Pressure Variability
(AOP Variability). Heart rate and systolic aortic pressure variability were
measured to quantify cardiac sympathovagal balance and pressure lability respec-
tively8,9. Details of the method of spectral analysis have been published previ-
ously8. This method was chosen because it referred to a study in both dogs and
humans and spectral analysis of our data confirmed that the frequency peaks of
heart rate and arterial pressure variability were within the suggested predeter-
mined frequency bands. In short: an artefact-free stationary time series of
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Figure 1. Flow chart of our study protocol in chloralose-anesthetized dogs. HRV, heart rate and
arterial pressure variability;BL,baseline;BCO,bicarotid occlusion;BST,cardiac barosensitivity test;
Esmo, esmolol; Dex, dexmedetomidine
approximately 400 beats was selected from the ECG (lead II) signal. In case of a
non-sinus beat, this beat was discarded and replaced by the interpolated value.
Beat to beat systolic arterial pressure was calculated from the peak of the aortic
pressure signal. Spectral components and associated power of the heart rate and
arterial pressure data were computed using a computer program based on Fast
Fourier analysis.From these computed spectra the power (dB) of total frequency
(TF: 0.02 – 0.35 Hz), low frequency (LF: 0.02 – 0.12 Hz), and high frequency
(HF: 0.25 – 0.35 Hz) was calculated for each experimental period.
Blood samples
All blood samples were collected on ice, centrifuged at 4° C, and stored as
plasma at –70°C.
Plasma concentrations of dexmedetomidine were determined by gas chro-
matography-mass spectrometry10 at Farmos research, Turku, Finland.
Plasma norepinephrine concentrations were measured as an indicator of
sympathetic tone and were analyzed with high performance liquid chromatog-
raphy with colorimetric electrochemical detection11.
Bilateral Carotid artery Occlusion (BCO). To evaluate carotid baroreceptor func-
tion, both common carotid arteries were occluded for 3 minutes as described
previously12, 13 and we measured; the carotid pressure distal to the occlusion,
heart rate, aortic pressure, and plasma norepinephrine concentrations.Responses
were calculated as the difference between the value measured during carotid
occlusion (after maximal changes had stabilized) and the value measured imme-
diately before carotid occlusion. The gain of the carotid pressure response, as a
measure of the baroreceptor mediated vascular response, was calculated as the
ratio of the increase in systolic aortic pressure to the decrease in systolic carotid
artery pressure.
Cardiac Baroreceptor Sensitivity Test (cardiac BST): Arterial pressure was randomly
varied within a range of 50 mmHg above and below baseline by inflating the
intravascular balloons.The number of pressure changes for each test was approx-
imately 9, and their duration was approximately 30 seconds. The resulting heart
rates and arterial pressures were stored for off line analysis. The mean value of
systolic aortic pressure and heart rate (sinus rhythm) over the final 10-15 s of
each pressure change were calculated. The gain of cardiac baroreceptor reflex
sensitivity was calculated as the slope of the regression line relating systolic arte-
rial pressure (mmHg) to heart rate (beats per min (bpm)). Additionally, the
maximal and minimal heart rate values obtained during each test were calcu-
lated as measures of sympathetic and parasympathetic cardiac modulation
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respectively. Cardiac BST was not repeated during control 2 because this would
increase the length of the experiment too much.
Statistical analysis
Cardiac BST data from two out of the eleven dogs were missing because of
technical problems. These two dogs were excluded from our analysis because
cardiac BST was our main outcome measure. Power analysis indicated that the
present study was powered to detect a 50% difference in baroslope changes
(power:0.80 and α =0.05).Because of the relatively low number of experiments
the non-parametric Wilcoxon signed rank test was used to analyse the data.The
effects of esmolol and dexmedetomidine were compared to each other and to
their preceding control measurements. To minimize a possible time-effect in
comparing esmolol and dexmedetomidine values, statistical testing was done on
values from which their preceding control values were subtracted.For analysis of
the cardiac BST, for which Control 2 measurement was not done, repeated
measures analysis (Friedman test) followed by Wilcoxon Signed Ranked test and
Bonferroni correction was used. A P-value of  0.05 was considered statistically
significant. Data are presented as mean (SD), unless stated otherwise.
Results
Baseline experimental conditions
Esmolol infusion did not affect plasma norepinephrine concentrations (table 1),
and resulted in adequate beta-adrenergic blockade because it abolished the
response to the tachycardic of dose isoprenaline (mean dose 0.45 (0.04) μg kg-1)
in all experiments. The infusion scheme of dexmedetomidine resulted in
dexmedetomidine plasma concentrations of 0.94 (0.33 – 3.49) ng mL-1 (median
(range)), and was associated with a decrease in plasma norepinephrine concen-
trations of more than 75% (Table 1). During baseline dexmedetomidine
decreased heart rate more than esmolol but neither drug affected arterial pres-
sure (Table 1).
Heart rate and arterial pressure variability.
Neither drug affected total spectral frequency power of heart rate and arterial
pressure variability (data not shown). Dexmedetomidine increased the power of
the HF component of heart rate variability and this was associated with a
decrease in power of the LF component of systolic arterial pressure variability. In
contrast, esmolol did not affect power of any of the frequency spectra (Fig. 2).
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Bilateral Carotid artery Occlusion
Dexmedetomidine, but not esmolol, suppressed the carotid baroreceptor medi-
ated increase in plasma concentration of norepinephrine and the increase in
systolic arterial pressure (table 1, BCO effect). Simultaneously, carotid artery
pressure distal to the carotid occlusion decreased more in presence of
dexmedetomidine than in presence of esmolol (table 1). This suppression of the
carotid baroreceptor mediated vasopressor response from dexmedetomidine in
contrast to the maintained response from esmolol is shown in figure 3 as their
different effects on the calculated pressure gain (ratio of the increase in systolic
aortic pressure to the decrease in systolic carotid artery pressure).
Cardiac Barosensitivity Test
The range of arterial pressures used to test cardiac barosensitivity was similar
during each study period (Control 1: 78 - 178 mmHg, Esmo: 70 - 170 mmHg,
Dexmed: 81 - 181 mmHg, P > 0.05). However, the resulting slope and range of
heart rate responses were different during each period of measurement as can be
seen in a typical example (Fig. 4). Esmolol almost abolished the slope of cardiac
barosensitivity; in contrast, dexmedetomidine maintained this slope (Fig 5,
upper panel).Dexmedetomidine and esmolol suppressed the maximal heart rate
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Table 1: Baseline values and effect of bicarotid occlusion (BCO) (mean (SD))during the sequential
study periods. BCO-effect = BCO value minus baseline value.
Variable Control 1 Esmolol Control 2 Dexmedetomidine
Norepinephrine
nmol L-1
Baseline 0.36 (0.24) 0.50 (0.39) 0.67 (0.55) 0.11 (0.15)*#
BCO-effect 0.28 (0.25) 0.16 (0.20) 0.09 (0.09) -0.06 (0.12)*
Heart rate
beats min-1
Baseline 160 (20) 138 (13)* 150 (18) 101 (20)*#
BCO-effect 12 (6) 3 (3)* 7 (2) 18 (15)#
Syst Aortic pressure
mmHg
Baseline 127 (20) 127 (18) 128 (12) 139 (25)
BCO-effect 36 (19) 26 (10) 32 (6) 14 (9)*
Syst Carotid pressure
mmHg
BCO-effect - 31 (18) -24 (9) -21 (12) -34 (15)#
* P  0.05 compared to preceding control; # P  0.05 esmolol compared to dexmedetomidine.
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Figure 2.Individual changes in power of Low Frequency (LF) and High Frequency (HF) heart rate
variability (upper and middle panels) and LF arterial pressure variability (lower panels). Esmo :during
esmolol infusion,Dexmed:during dexmedetomidine infusion * = P  0.05 compared to preceding
control measurement. # = P  0.05 Dexmed compared to Esmo.Dexmedetomidine increased HF
heart rate variability and depressed LF arterial pressure variability compared to esmolol.dexmedeto-
midine
plateau in response to a decrease in arterial pressure to a similar extend (Fig. 5,
middle panel). However, only dexmedetomidine decreased the minimum heart
rate plateau to an increase in arterial pressure (Fig. 5, lower panel). As a result,
dexmedetomidine but not esmolol maintained the heart rate range in response
to arterial pressure variation (heart rate range: Control 1: 58 (34), Esmo: 17 (14),
Dexmed:55 (18) bpm).Of notice, some dogs developed severe nodal or ventric-
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Figure 3.Individual changes in arterial pressure gain calculated as the ratio of the increase in systolic
arterial pressure to the decrease in systolic carotid pressure during bicarotid artery occlusion.
Dexmedetomidine decreased this gain compared to the preceding control measurement in all expe-
riments.Esmo:during esmolol infusion,Dexmed:during dexmedetomidine infusion.* = P ≤ 0.05
compared to preceding control measurement.dexmedetomidine
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Figure 4.Example of changes in cardiac baroreceptor sensitivity during the sequential experimental
conditions in one of the dogs. White dots: baseline values, black dots: values measured during
induced pressure changes. Esmolol (esmo) almost abolished the slope relating heart rate responses
(y-axis) to changes in systolic arterial pressure (x-axis).Dexmedetomidine maintained this slope at
lower heart rate values compared to control.
ular brady-arrhythmias upon maximal inflation of the aortic balloon in presence
of dexmedetomidine. However, these arrhythmias resolved spontaneously after
deflating the balloon, and only tests without arrhythmias were included in the
analysis.
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Figure 5. Effects of esmolol (esmo) and dexmedetomidine (dexmed) on cardiac barosensitivity.
Data indicate individual results of the slope of the regression line relating heart rate to systolic arterial
pressure (upper panel),maximal heart rate response (middle panel),and minimal heart rate response
(lower panel).*= P < 0.05 compared to control 1 .#= P < 0.05 dexmed compared to esmo.dexme-
detomidine
Discussion
This is the first comparative study of two different classes of sympatholytic drugs
on different measures of baroreceptor function.Arterial baroreflex function is an
important regulatory system in maintaining cardiovascular stability, and consists
of a cardiac and a vascular effector limb. The current study in chloralose-anaes-
thetized dogs shows several important differences between the alpha2-agonist
dexmedetomidine and the beta1-antagonist esmolol on arterial baroreflex func-
tion.
The most important difference was that dexmedetomidine but not esmolol
maintained cardiac baroreceptor gain, as indicated by their effects on the cardiac
barosensitivity slope. This maintained cardiac baroreceptor gain from
dexmedetomidine is in accordance with previous studies in dogs14 and human
volunteers15. However, the depressed baroreceptor gain from esmolol contrasts
with previous findings which indicate that beta-blockade either has no effect16
or even improves cardiac baroreflex function9. Differences in methods may
explain these contrasting results because in these previous studies cardiac
barosensitivity was assessed from rapid changes in arterial pressure, which
measures mainly vagally mediated heart rate changes17. In contrast, we studied
cardiac barosensitivity from “steady state” pressure changes, which measures
both the sympathetic and parasympathetic mediated component of the heart
rate response.
Our data suggest that the differences in cardiac baroreceptor sensitivity
between esmolol and dexmedetomidine may be explained from their effects on
cardiac vagal tone. Both drugs decreased the sympathetic controlled maximal
heart rate plateau to a similar extend, but only dexmedetomidine increased
cardiac vagal tone. This is indicated by a lower minimum heart rate plateau
during cardiac barosensitivity testing, and by the increase in power of the HF
component of heart rate variablility, an accurate measure of cardiac vagal tone at
rest18. As a result dexmedetomidine maintained the operating range of the
baroreflex system. In contrast, the pure sympatholytic effect of esmolol
decreased the range and thus the slope of heart rate responses. Our findings fit
well with recent observations in mice19 and humans20 suggesting that the bene-
ficial effect of alpha2-agonists on baroreceptor sensitivity is mediated by the
parasympathetic nervous system. The mechanisms by which alpha2-agonists
enhance this parasympathetic mediated heart rate control are not known but
they may directly influence α2-adrenoreceptors in the vagal nuclei of the
medulla oblongata 21. Previous data on parasympathetic effects from beta
blockade are equivocal, showing that beta blockade either increases16,22 or, in
accordance with the current findings, has no parasympathetic effect18,19. These
conflicting results may be explained by the various conditions determining the
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vagal HF component of heart rate variability such as; baseline autonomic tone23,
acute versus chronic beta blockade8, and the specific beta-blocker studied24.
The increased vagal tone and maintainance of baroreceptor gain of
dexmedetomidine resulted in an improved hemodynamic stability, as indicated
by its suppression of the LF power of arterial pressure variability9. In accordance,
it has been shown that rapid cardiac vagal modulation is the most important
mechanism for correcting high frequency, small magnitude, blood pressure vari-
ations25. Also, the alpha2-agonist clonidine has been shown to have a
hemodynamic stabilizing effect during the recovery period in patients with
hypertension3.
These differences in cardiac autonomic control between dexmedetomidine
and esmolol may be clinically relevant because indices of impaired cardiovas-
cular control have been shown to be independent predictors of adverse
outcome after myocardial infarction26 or after noncardiac surgery5. However,
extrapolation from animal studies should be done with caution.
In addition to these different effects on the cardiac limb of the baroreceptor
reflex, the current study indicates that dexmedetomidine and esmolol had also
different effects on the vascular effector limb. Their effects on arterial pressure
gain and plasma norepinephrine response during carotid artery occlusion indi-
cate that dexmedetomidine suppressed and esmolol maintained the sympathetic
mediated vasopressor response. The conclusions of previous studies on the
effects of alpha2-agonists on sympathetic mediated increases of vascular tone are
equivocal. In accordance with the current study, dexmedetomidine attenuated
the vasoconstrictor response to hypotension in rabbits27 and clonidine decreased
the slope of the arterial pressure – sympathetic nerve activity relationship in
human volunteers20. It is likely that this reduced sympathetic vasopressor
response results from their effects at α2-receptors in vasomotor centres in the
brainstem28, and at pre- and post sympathetic ganglia29. In contrast, alpha2-
agonists have been shown to maintain adaptive sympathetic vasopressor
responses during potential major decreases in blood pressure such as sepsis30 or
vessel unclamping during liver transplantation31. These contrasting effects of
alpha2-agonists on sympathetic vasopressor responses may be explained because
central pathways different from baroreceptor pathways are involved during
hypovolemic episodes32. In the current study beta-blockade did not affect the
sympathetic vasopressor response which is in accordance with findings in
human volunteers showing that propanolol does not attenuate the increase in
sympathetic nerve activity during orthostatic stress 33.
The results of this study must be interpreted within the constraints of several
limitations. First, it is likely that anaesthesia affected our results. However,
chloralose anaesthesia is used widely for neurophysiological experiments and
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offers stable hemodynamics34. The presence of anesthesia and controlled venti-
lation also prevented uncontrolled emotional stress responses and irregular
respiration, which are known to interfere with neurophysiological measure-
ments. Another limitation is that the counter regulatory response from the
aortic baroreceptors depressed the arterial pressure response during carotid
occlusion35, thus interfering with the calculation of the pressure gain. However
it is likely that this confounding factor had a similar effect during all periods of
measurement.
In conclusion, in accordance with our hypothesis we found that an alpha2-
agonist and a beta-blocker had different baroreceptor effects.Dexmedetomidine
maintained baroreceptor mediated heart rate responses and improved baseline
arterial pressure stability from its vagomimetic effect but decreased vascular
responsiveness from its central sympatholytic effect. In contrast, peripheral
cardiac sympatholysis from esmolol depressed the cardiac effector limb of the
baroreceptor but maintained central sympathetic mediated vascular responsive-
ness.
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General discussion
Based on the findings in the current thesis there are three major topics which
deserve further discussion:
1. Strategies to modulate the perioperative stress response: improving knowl-
edge.
2. Choosing the optimal sympatholytic drug to decrease perioperative
myocardial ischemia.
3. Decreasing the stress response, what is the goal ?
Strategies to modulate the perioperative stress response:
improving knowledge
The introduction of anesthesia and the associated reduction in the perioperative
stress response was a major step forward in improving morbidity and mortality
after surgery. However, modern surgery is still associated with adverse outcome
related to the surgical stress response. This is mainly due to adverse cardiac
outcome during the first weeks to months after surgery. At this moment clinical
studies do not allow definitive conclusions regarding the effectiveness of anes-
thetic strategies on cardiac outcome. This can be explained by: 1) the low inci-
dence of adverse cardiac outcome, 2) the presence of confounding factors and,
3) the difficulty in defining and thus measuring adverse cardiac outcome.There-
fore great efforts will be needed to overcome these difficulties in studying the
effectiveness of anesthetic techniques on cardiac outcome.An alternative way to
increase our knowledge on the relationship between anesthetic strategies and
adverse outcome is to study the effect of anesthetic strategies on the stress
response to surgery instead of studying their effect on cardiac outcome. Our
study in chapter 3 of this thesis is an example of this strategy. In this study the
effect of an opioid based anesthetic technique and an epidural technique on the
early postoperative stress response were compared. Our main finding was that
the plasma concentration of epinephrine was higher and that of the pro-inflam-
matory cytokine IL-6 was lower in presence of an opioid based anesthetic
compared to an epidural based anesthetic.These findings highlight the potential
of anesthetic techniques to modulate both the neuro-endocrine and the immu-
nological homeostatic responses to surgery. However, it is difficult to define the
implications of our findings. Firstly, this is because all patients had an uneventful
recovery.A second difficulty in interpreting our results is that we measured rela-
tively few markers of the stress response. For example, we did not measure
cortisol, anti-inflammatory cytokines, and lymphocyte function.Finally,because
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of large inter-individual variations in markers of the stress response it is difficult
to compare our findings to those in other studies having different study designs .
To increase our knowledge on anesthetic modulation of the stress response as
such we need an enormous amount of data. One possibility is to create an
extensive database of patients having surgery.This database should include serial
measurements of different markers of the stress response and variables such as
surgical procedure, anesthetic technique, and co-morbidity of the patient. In this
way we may identify factors, including anesthetic strategy, associated with an
excessive or inadequate stress response (fig.1). The resulting knowledge may
help to define the optimal perioperative strategy for an individual patient. For
example, our findings in chapter 3 suggest that an opioid-based technique is
superior in decreasing the inflammatory response to surgery whereas an
epidural based technique has superior sympatholytic effects. If this suggestion is
confirmed in such a database then we may use an opioid technique if the
inflammatory response is to be suppressed, and an epidural technique if
decreasing sympathetic activation is important for an individual patient. In the
future genetic data may be added as a variable to such a database.This is because
there is increasing evidence that differences in genetic expression or genetic
polymorphisms are responsible for more than 50% of the individual differences
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Figure 1
Schematic presentation of different factors which modify outcome after surgery indi-
rectly from their effects on the stress response to tissue injury.
in the stress response2. For instance, genetic variants in cytokine and leukocyte-
endothelial interaction pathways are independently associated with severity of
myocardial necrosis after cardiac surgery3. Also, it has been identified that a
single-nucleotide polymorphism of the alpha2-adrenoreceptor contributes to
autonomic nervous system responsiveness 4.
Choosing the optimal sympatholytic drug to decrease
myocardial ischemia after surgery
Clinical studies indicate that sympatholytic drugs decrease perioperative
myocardial ischemia. An important draw-back of these studies is the absence of
an accepted gold standard indicator for the diagnosis of perioperative myocardial
ischemia or myocardial infarction5.This beneficial effect of sympatholytic drugs
on myocardial ischemia may result from suppressing shear stress on unstable
coronary plaques thus decreasing plaque rupture and coronary thrombosis.Also,
they may attenuate potentially dangerous mismatches in myocardial oxygen
demand and supply in presence of a severe stable coronary stenosis. However,
these two potential mechanisms are difficult to separate in patients. In this
context, the results of our study in dogs on the anti-ischemic effects of
perioperative sympatholysis are important (chapter 4). The experimental model
used in this study excluded coronary plaque rupture as a cause of myocardial
ischemia because coronary artery stenosis resulted from an occluder applied
around a coronary artery. In this way we were able to show that profound
perioperative sympatholysis has the potential to decrease myocardial ischemia
purely from its effect on myocardial oxygen balance. Another important aspect
of this study in dogs is that myocardial ischemia was diagnosed using its gold
standard indicator: myocardial lactate release.
The American Heart Association advised the use of either an alpha2-agonist
or a beta-blocker for perioperative pharmacological sympatholysis6. Central
sympatholysis produced by an alpha2-agonist may have a potential advantage
over the use of a beta-blocker because of the ability of the alpha2-agonist to
attenuate the adverse effects of sympathetic nervous stimulation mediated by
peripheral alpha- as well as beta receptors. However, there are no clinical studies
in which the potential anti-ischemic effects of alpha2-agonists are directly
compared to those of beta-blockers7. The main drawback of performing such a
comparative study is the enormous number of patients needed. At this moment
the first adequately powered randomised controlled trial on perioperative beta-
blockers (POISE trial) plans to recruit 10.000 patients8. It is likely that many
more patients are needed to find a difference between two potentially effective
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sympatholytic therapies. Therefore it is unlikely that both sympatholytic thera-
pies have clinically relevant different anti-ischemic effects.
This leaves us with the question: should we use alpha2-agonists or beta-
blockers for perioperative pharmacological sympatholysis ? The results of the
experimental studies in this thesis do not give a definite answer to this question.
However, they clearly show several differences between both classes of drugs
which may help to answer this question. Firstly, findings from this thesis suggest
that an alpha2-agonist decreases heart rate more than a beta-blocker (chapter 7).
This was explained by the additional vagomimetic action of the alpha2-agonist
in contrast to the pure cardiac sympatholytic effect of the beta-blocker. In
accordance with our findings, a case report indicated that dexmedetomidine
was more successful than esmolol in treating intraoperative tachycardia 9. The
effect of a drug on heart rate seems to be important for its effect on myocardial
ischemia.This is because in our study in dogs emerging from anesthesia (chapter
4) a decreased heart rate from pharmacological sympatholysis was associated
with and an improved myocardial blood flow through a stenotic coronary artery.
Also clinical studies show the importance of heart rate in decreasing myocardial
ischemia. In a study in patients having vascular surgery the use of beta-blockers
to keep the heart rate below the pre-operative measured ischemic threshold
markedly reduced postoperative myocardial ischemia 10. In another study, a tight
heart rate control with beta-blockers was associated with reduced perioperative
myocardial ischemia and troponin T 11. Myocardial oxygen balance may also
improve from a decrease in myocardial oxygen demand. However, the findings
in our study in dogs emerging from anesthesia suggest that sympatholysis has no
significant effect on myocardial oxygen demand (chapter 4). Also, our findings
in chapter 5 and 6 suggest that neither an alpha2-agonist nor a beta-blocker has
an important effect on myocardial oxygen demand. In these studies in dogs,
myocardial oxygen demand was measured from its effect on myocardial oxygen
consumption in presence of an unlimited coronary blood flow. This measure-
ment of demand is more accurate than a hemodynamic index of demand, such
as rate pressure product, which is generally used in clinical studies (chapter 5).
Thus, it is likely that, in presence of a critical coronary artery stenosis, the heart
rate lowering effect of sympatholytic drugs improves myocardial oxygen balance
from an increase in myocardial oxygen supply. Therefore, these findings present
a reason to study the heart rate lowering effects of beta-blockers and alpha2-
agonists during the period early after surgery.
Secondly, our findings suggest that an alpha2-agonist, in contrast to a beta-
blocker suppresses stress related increases in systemic vascular resistance (SVR)
(chapter 6). An increase in SVR is an important component of the
hemodynamic response to mental stress. It is likely that mental stress from
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anxiety and pain is part of the postoperative stress. There are indications that
increases in SVR may cause myocardial ischemia in patients having left ventric-
ular dysfunction. It has been shown that beta-blockers may be harmful in
patients having mental-stress induced myocardial ischemia12. Therefore, an
alpha2-agonist may be a more appropriate sympatholytic drug than a beta-
blocker in these patients.Additionally, alpha2-agonists may decrease mental stress
from their sedative and anxiolytic properties.
Finally, the findings in this thesis indicate that alpha2-agonists and beta-
blockers have different effects on baroreceptor mediated cardiovascular control.
This difference may be important because indices of impaired cardiovascular
control are independent predictors of adverse outcome after surgery13. First, we
found that the alpha2-agonist dexmedetomidine maintained baroreceptor sensi-
tivity and baseline hemodynamic stability better than the beta-blocker esmolol
(chapter 4). Additionally, the increase in cardiac vagal tone from the alpha2-
agonist was associated with an improved ability to correct high frequency, small
magnitude, blood pressure variations14. A second difference regarding cardiovas-
cular control mechanisms was that the alpha2-agonist, in contrast to the beta-
blocker, suppressed the sympathetic vasoconstrictor response.However, the clin-
ical relevance of this potential disadvantageous effect of an alpha2-agonist is
difficult to predict.There is, on the one hand, a large body of clinical experience
of perioperative use of alpha2-agonists and no major complications have so far
been published. Additionally, several case-reports have shown that alpha2-
agonists maintain adaptive sympathetic vasopressor responses during potential
major decreases in blood pressure such as sepsis15or from vessel unclamping
during liver transplantation16. An explanation for this maintained sympathetic
response in the presence of an alpha2-agonist is that central pathways different
from baroreceptor pathways are involved during hypovolemic episodes17. On
the other hand, there is evidence that suppression of sympathetic mediated
compensatory mechanisms may be disadvantageous in some patient groups. For
example, the Moxonidine Congestive Heart Failure Trial (MOXCON) showed
that moxonidine, a centrally active sympatholytic imidazoline agonist, increased
mortality by more than 50% in patients having severe heart failure18,19. Also, the
beta-Blocker Evaluation of Survival Trial (BEST) showed that powerful
sympatholyis increased mortality in patients having severe heart failure20. These
two trials caution against unbounded sympatholysis and may present a reason to
study the relation between perioperative sympatholysis and potential shock
states. Thus, the main findings from our comparative experimental studies on
autonomic nervous system modulation of an alpha2-agonist and a beta-blocker
were:
1. The vagomimetic effect of the alpha2-agonist resulted in a lower heart rate.
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2. In contrast to the beta-blocker, the alpha2-agonist maintained baroreceptor
mediated heart rate responses.
3. The alpha2-agonist suppressed the increase in vascular resistance to a stress
stimulus more effectively.
In conclusion, the findings in this thesis suggest that an alpha2-agonist may be
more appropriate than a beta-blocker for perioperative sympatholysis.However,
studies in patients are needed before more firm advise can be given.
Decreasing the stress response, what is the goal ?
One view is that the stress response to surgery should be maximally suppressed
because it may have adverse effects and is not necessary for survival in hospita-
lised surgical patients 21.
Another view is not to intervene aggressively in the stress response.The stress
response was programmed in higher organisms to provide homeostatic adjust-
ments to cold, volume loss, hypoglycaemia, and infection. In accordance with
this view, Cannon showed 70 years ago that total sympathectomized cats were
unable to defend themselves against various stresses such as hypoxia, temperature
changes and hemorrhage22. The over-aggressive use of therapies to decrease the
stress response may be harmful in patients as well. For example, the use of
opioids in intensive care patients may have detrimental effects such as increased
haemodynamic instability during shock, and suppression of host immune
responses23. Also, some patients have a defective stress-response secondary to
their illness, and suppressing the stress response in these patients may have detri-
mental effects. For example, Rivers and colleagues24 reported that a significant
number of patients who needed vasopressor therapy early after surgery had signs
of adrenal insufficiency. The administration of the stress hormone hydrocorti-
sone decreased vasopressor requirement and improved survival in these patients.
Finally, there are strong indications that intense sympatholytic therapy may be
detrimental in patients having severe cardiac failure18 20.
In conclusion, to improve perioperative outcome the surgical team should
aim to control the stress response in relation to the individual patient. However,
precise control of the different components of the surgical stress response is not
possible at this moment.Also, it is difficult to predict which patients are at risk of
an inappropiate stress response.Therefore, controlling the stress response in rela-
tion to the individual patient is a major task in future perioperative medicine.At
this moment, we have to continue our current practice of aiming at a profound
suppression of the stress response to surgery. However, we must realize that this
strategy places large responsibility on care providers to monitor and protect
their patients during the perioperative period.
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